<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="http://www.effectivemedicine.org/wp-content/plugins/google-sitemap-generator/sitemap.xsl"?><!-- generator="wordpress/3.2.1" -->
<!-- sitemap-generator-url="http://www.arnebrachhold.de" sitemap-generator-version="3.2.5" -->
<!-- generated-on="February 22, 2012 9:41 pm" -->
<!-- Debug: Total comment count: 0 -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">	<url>
		<loc>http://www.effectivemedicine.org/</loc>
		<lastmod>2012-02-22T21:36:12+00:00</lastmod>
		<changefreq>daily</changefreq>
		<priority>1.0</priority>
	</url>
<!-- Debug: Start Postings -->
<!-- Debug: Priority report of postID 787: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/22/class-i-medical-device-recall-carefusion-nicoletone-software-used-with-carefusion-cortical-stimulator-control-unit/</loc>
		<lastmod>2012-02-22T21:36:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 786: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/22/summary-information-for-berlin-heart-excor-pediatric-ventricular-assist-device-vad/</loc>
		<lastmod>2012-02-22T21:36:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 785: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/22/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-importantes-interacciones-entre-el-medicamento-victrelis-boceprevir-y-los-medicamentos-inhibidores-de-la-proteasa-del-virus-de-inmunodefi/</loc>
		<lastmod>2012-02-22T15:16:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 784: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/21/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-la-diarrea-asociada-con-clostridum-difficile-puede-estar-relacionada-con-los-medicamentos-contra-la-acidez-estomacal-denominados-inhibidore/</loc>
		<lastmod>2012-02-22T03:10:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 783: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/21/january-2012/</loc>
		<lastmod>2012-02-21T21:08:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 782: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/18/premarket-approval-pma-summary-review-memos-for-180-day-design-changes-p050044s019-added/</loc>
		<lastmod>2012-02-18T08:16:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 781: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/18/infants%e2%80%99-tylenol-oral-suspension-1-oz-grape-recall/</loc>
		<lastmod>2012-02-18T08:16:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 780: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/17/draft-guidance-for-industry-providing-regulatory-submissions-in-electronic-format/</loc>
		<lastmod>2012-02-17T20:04:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 779: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/17/cdrh-transparency-515-program-initiative-status-update/</loc>
		<lastmod>2012-02-17T20:04:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 778: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/16/public-workshop-5/</loc>
		<lastmod>2012-02-16T19:15:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 777: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/16/fda-safety-communication-choking-hazard-and-serious-injuries-with-the-spinbrush-line-of-powered-toothbrushes/</loc>
		<lastmod>2012-02-16T19:15:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 776: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/16/evaluation-of-automatic-class-iii-designation-de-novo-decision-k102333-approval-letter-added/</loc>
		<lastmod>2012-02-16T19:14:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 775: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/16/spinbrush-powered-toothbrush-by-arm-and-hammer-or-crest-safety-communication/</loc>
		<lastmod>2012-02-16T19:14:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 774: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/15/fda-drug-safety-communication-planned-return-of-cardiogen-82-to-market-with-new-boxed-warning/</loc>
		<lastmod>2012-02-16T00:49:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 773: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/15/avastin-bevacizumab-counterfeit-product/</loc>
		<lastmod>2012-02-15T06:20:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 772: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/14/salter-labs-7600-bubble-humidifier-used-with-supplemental-oxygen-therapy-class-i-recall/</loc>
		<lastmod>2012-02-14T17:57:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 771: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/14/class-i-medical-device-recall-salter-labs-7600-bubble-humidifier-used-with-supplemental-oxygen-therapy/</loc>
		<lastmod>2012-02-14T05:34:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 770: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/13/neurological-devices-panel-of-the-medical-devices-advisory-committee-meeting-announcement-march-23-2012/</loc>
		<lastmod>2012-02-13T17:33:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 769: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/13/regenarouse-recall/</loc>
		<lastmod>2012-02-13T17:33:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 768: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/11/hand-held-dental-x-ray-units-fda-safety-communication/</loc>
		<lastmod>2012-02-11T14:45:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 767: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/11/wholistic-herbs-inc-koff-and-kold-and-kold-sore-spray-recall-non/</loc>
		<lastmod>2012-02-11T14:45:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 766: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/10/fda-safety-communication-illegal-sale-of-potentially-unsafe-hand-held-dental-x-ray-units/</loc>
		<lastmod>2012-02-11T02:23:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 765: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/10/evaluation-of-automatic-class-iii-designation-de-novo-decision-k112394-added/</loc>
		<lastmod>2012-02-11T02:23:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 764: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/10/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-nuevo-factor-de-riesgo-para-la-leucoencefalopatia-multifocal-progresiva-pml-por-sus-siglas-en-ingles-relacionado-con-tysabri-natalizumab/</loc>
		<lastmod>2012-02-10T20:04:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 763: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/10/transcripts-of-january-11-2012-gastroenterology-urology-devices-panel-meeting/</loc>
		<lastmod>2012-02-10T13:40:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 762: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/09/victrelis-boceprevir-and-ritonavir-boosted-human-immunodeficiency-virus-hiv-protease-inhibitor-drugs-drug-safety-communication/</loc>
		<lastmod>2012-02-10T01:08:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 761: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/09/fda-drug-safety-communication-important-drug-interactions-between-victrelis-boceprevir-and-ritonavir-boosted-human-immunodeficiency-virus-hiv-protease-inhibitor-drugs/</loc>
		<lastmod>2012-02-09T06:30:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 760: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/08/meeting-materials-for-the-neurological-devices-panel-meeting-to-be-held-on-21012/</loc>
		<lastmod>2012-02-09T00:17:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 759: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/08/proton-pump-inhibitors-ppis-drug-safety-communication-clostridium-difficile/</loc>
		<lastmod>2012-02-09T00:17:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 758: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/08/prescription-to-over-the-counter-otc-switch-list/</loc>
		<lastmod>2012-02-08T18:03:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 757: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/08/fda-drug-safety-communication-clostridium-difficile-associated-diarrhea-can-be-associated-with-stomach-acid-drugs-known-as-proton-pump-inhibitors-ppis/</loc>
		<lastmod>2012-02-08T18:03:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 756: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/07/resources-and-tools-for-preventing-surgical-fires/</loc>
		<lastmod>2012-02-07T04:59:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 755: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/06/public-workshop-cardiovascular-metallic-implants-corrosion-surface-characterization-and-nickel-leaching-march-8/</loc>
		<lastmod>2012-02-06T22:58:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 754: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/06/healthy-people-co-dietary-supplements-recall/</loc>
		<lastmod>2012-02-06T22:58:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 753: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/04/gris-peg-griseofulvin-ultramicrosize-health-advisory-risk-of-product-mix/</loc>
		<lastmod>2012-02-04T09:27:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 752: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/03/initiative-partners/</loc>
		<lastmod>2012-02-04T03:22:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 751: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/03/acetylcysteine-solution-usp-roxane-laboratories-inc-recall/</loc>
		<lastmod>2012-02-03T21:18:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 750: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/03/summary-information-for-therapy-cool-path-duo-ablation-catheter-safire-blu-duo-ablation-catheter-and-ibi1500t9-cp-v1-6-cardiac-ablation-generator/</loc>
		<lastmod>2012-02-03T08:41:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 749: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/03/consumer-information-on-therapy-cool-path-duo-ablation-catheter-safire-blu-duo-ablation-catheter-and-ibi1500t9-cp-v1-6-cardiac-ablation-generator/</loc>
		<lastmod>2012-02-03T08:41:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 748: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/01/loovral-28-norgestrelethinylestradiol-tablets-recall/</loc>
		<lastmod>2012-02-01T20:05:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 747: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/31/vitaflo-usa-renastart-recall/</loc>
		<lastmod>2012-01-31T20:00:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 746: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/30/treanda-bendamustine-hcl-recall/</loc>
		<lastmod>2012-01-30T19:30:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 745: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/30/evaluation-of-automatic-class-iii-designation-de-novo-decision-k093295-added/</loc>
		<lastmod>2012-01-30T06:29:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 743: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/28/summary-information-for-m-vu-algorithm-engine/</loc>
		<lastmod>2012-01-28T05:16:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 744: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/28/consumer-information-on-m-vu-algorithm-engine/</loc>
		<lastmod>2012-01-28T05:16:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 735: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-2/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 736: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-3/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 737: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-4/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 738: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-4/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 739: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-5/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 740: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-5/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 741: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-6/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 742: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/26/cdrh-ombudsman-annual-report-7/</loc>
		<lastmod>2012-01-26T16:09:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 734: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/25/pma-final-decisions-for-december-2011/</loc>
		<lastmod>2012-01-26T03:34:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 733: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/25/summary-information-for-melafind/</loc>
		<lastmod>2012-01-26T03:34:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 732: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/25/fda-report-on-mdufma-mdufa-performance-october-21-2011-pdf/</loc>
		<lastmod>2012-01-26T03:34:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 731: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/24/cdrh-2012-strategic-priorities/</loc>
		<lastmod>2012-01-24T14:12:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 730: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/24/consumer-information-on-advia-centaur-anti-hbs2-ahbs2-assay-and-advia-centaur-anti-hbs2-ahbs2-quality-control-material-for-use-on-the-advia-centaur-and-advia-centaur-xp-sy/</loc>
		<lastmod>2012-01-24T14:12:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 729: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/24/summary-information-for-advia-centaur-anti-hbs2-ahbs2-assay-and-advia-centaur-anti-hbs2-ahbs2-quality-control-material-for-use-on-the-advia-centaur-and-advia-centaur-xp-sy/</loc>
		<lastmod>2012-01-24T14:12:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 728: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/23/premarket-approval-pma-summary-review-memos-for-180-day-design-changes-new-memos-available-2/</loc>
		<lastmod>2012-01-23T13:43:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 727: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/21/fda-drug-safety-communication-new-risk-factor-for-progressive-multifocal-leukoencephalopathy-pml-associated-with-tysabri-natalizumab/</loc>
		<lastmod>2012-01-21T06:14:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 726: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/20/vagifresh-ball-vagifresh-gel-female-one-recall/</loc>
		<lastmod>2012-01-21T00:13:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 725: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/20/perfect-image-solutions-topical-hair-regrowth-products-recall/</loc>
		<lastmod>2012-01-21T00:13:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 724: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/20/tysabri-natalizumab-drug-safety-communication/</loc>
		<lastmod>2012-01-21T00:13:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 722: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/19/summary-information-for-gore-tag-thoracic-endoprosthesis/</loc>
		<lastmod>2012-01-19T23:44:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 723: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/19/consumer-information-on-gore-tag-thoracic-endoprosthesis/</loc>
		<lastmod>2012-01-19T23:44:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 721: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/18/guidance-for-industry-preparation-of-ides-and-inds-for-products-intended-to-repair-or-replace-knee-cartilage-pdf/</loc>
		<lastmod>2012-01-18T23:25:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 720: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/18/medication-guides/</loc>
		<lastmod>2012-01-18T04:17:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 719: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/15/evaluation-of-automatic-class-iii-designation-de-novo-decision-summaries-k102333-added/</loc>
		<lastmod>2012-01-15T07:23:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 718: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/13/fda-drug-safety-communication-new-boxed-warning-and-contraindication-for-adcetris-brentuximab-vedotin/</loc>
		<lastmod>2012-01-14T00:13:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 717: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/13/evaluation-of-automatic-class-iii-designation-de-novo-decision-k080377-added/</loc>
		<lastmod>2012-01-13T18:01:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 716: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/13/adcetris-brentuximab-vedotin-drug-safety-communication/</loc>
		<lastmod>2012-01-13T18:01:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 715: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/13/class-i-medical-device-recall-respironics-inc-trilogy-100-ventilators/</loc>
		<lastmod>2012-01-13T05:57:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 713: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/13/respironics-inc-trilogy-100-ventilators-class-i-recall/</loc>
		<lastmod>2012-01-13T05:57:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 714: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/13/bedford-laboratories-polymyxin-b-for-injection-usp-and-vecuronium-bromide-for-injection-recall/</loc>
		<lastmod>2012-01-13T05:57:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 712: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/12/fda-drug-safety-communication-update-preliminary-findings-from-ongoing-investigations-of-cardiogen-82/</loc>
		<lastmod>2012-01-12T23:53:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 711: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/12/innovation-pathway/</loc>
		<lastmod>2012-01-12T17:52:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 710: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/12/consumer-information-on-berlin-heart-excor-pediatric-ventricular-assist-device-vad/</loc>
		<lastmod>2012-01-12T05:49:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 709: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/10/fda-drug-safety-communication-liver-injury-warning-to-be-removed-from-letairis-ambrisentan-tablets/</loc>
		<lastmod>2012-01-10T22:43:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 708: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/10/consumer-information-on-elecsys-anti-hbc-igm-immunoassay-and-elecsys-precicontrol-anti-hbc-igm-for-use-on-the-cobas-e-411-immunoassay-analyzer/</loc>
		<lastmod>2012-01-10T16:40:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 707: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/10/summary-information-for-elecsys-anti-hbc-igm-immunoassay-and-elecsys-precicontrol-anti-hbc-igm-for-use-on-the-cobas-e-411-immunoassay-analyzer/</loc>
		<lastmod>2012-01-10T16:40:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 705: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/10/consumer-information-on-bsd-2000-hyperthermia-system/</loc>
		<lastmod>2012-01-10T04:20:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 706: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/10/summary-information-for-bsd-2000-hyperthermia-system/</loc>
		<lastmod>2012-01-10T04:20:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 704: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/10/endo-pharmaceuticals-opiate-products-by-novartis-consumer-health-public-health-advisory/</loc>
		<lastmod>2012-01-10T04:20:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 703: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/09/novartis-consumer-health-over-the-counter-products-recall/</loc>
		<lastmod>2012-01-09T16:06:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 702: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/06/fda-statement-on-recently-terminated-clinical-trial-with-doribax-doripenem/</loc>
		<lastmod>2012-01-06T19:35:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 701: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/04/stress-urinary-incontinence/</loc>
		<lastmod>2012-01-05T00:01:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 700: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/04/class-i-medical-device-recall-ikaria-inomax-ds-drug-delivery-system/</loc>
		<lastmod>2012-01-05T00:01:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 699: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/04/ikaria-inomax-ds-drug-delivery-system-class-i-recall/</loc>
		<lastmod>2012-01-05T00:01:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 698: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/03/updated-cdrh-learn-course-list-spanish/</loc>
		<lastmod>2012-01-03T22:38:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 697: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/31/cdrh-learn-spanish-module/</loc>
		<lastmod>2011-12-31T08:45:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 696: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/30/draft-guidance-for-industry-and-food-and-drug-administration-staff-18/</loc>
		<lastmod>2011-12-30T20:34:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 695: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/29/questions-and-answers-fda-approves-a-class-risk-evaluation-and-mitigation-strategy-rems-for-transmucosal-immediate-release-fentanyl-tirf-medicines/</loc>
		<lastmod>2011-12-30T02:12:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 694: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/28/pma-final-decisions-for-november-2011/</loc>
		<lastmod>2011-12-28T06:10:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 693: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/27/sop-management-of-review-staff-changes-during-the-review-of-a-premarket-submission/</loc>
		<lastmod>2011-12-27T17:42:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 692: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/27/draft-guidance-for-industry-and-food-and-drug-administration-staff-17/</loc>
		<lastmod>2011-12-27T17:42:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 691: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/27/draft-guidance-for-industry-and-food-and-drug-administration-staff-16/</loc>
		<lastmod>2011-12-27T17:42:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 690: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/23/class-i-medical-device-recall-carefusion-avea-ventilator/</loc>
		<lastmod>2011-12-24T02:18:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 689: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/23/carefusion-avea-ventilator-recall/</loc>
		<lastmod>2011-12-24T02:18:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 688: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/23/fda-drug-safety-communication-addition-of-another-concentration-of-liquid-acetaminophen-marketed-for-infants/</loc>
		<lastmod>2011-12-23T07:40:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 687: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/22/steris-system-1-ss1-processor-second-6-month-extension-for-health-care-facilities-to-replace-steris-system-1-with-a-legally-marketed-alternative/</loc>
		<lastmod>2011-12-23T01:38:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 686: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/22/eclectic-institute-dietary-supplements-recall/</loc>
		<lastmod>2011-12-23T01:38:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 685: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/22/liquid-acetaminophen-marketed-for-infants-drug-safety-communication/</loc>
		<lastmod>2011-12-23T01:38:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 684: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/21/consumer-information-on-elecsys-anti-hbc-igm-immunoassay-and-elecsys-precicontrol-anti-hbc-igm-for-use-on-the-modular-analytics-e170-immunoassay-analyzer/</loc>
		<lastmod>2011-12-22T00:19:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 683: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/21/st-jude-medical-riata-and-riata-st-silicone-endocardial-defibrillation-leads-class-1-recall/</loc>
		<lastmod>2011-12-22T00:19:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 682: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/21/shoulderflex-massager-warning/</loc>
		<lastmod>2011-12-22T00:19:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 681: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/21/fda-drug-safety-communication-safety-review-of-a-reported-death-after-the-first-dose-of-multiple-sclerosis-drug-gilenya-fingolimod/</loc>
		<lastmod>2011-12-21T05:41:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 679: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/20/guidance-for-industry-and-food-and-drug-administration-staff-5/</loc>
		<lastmod>2011-12-20T23:33:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 680: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/20/class-i-medical-device-recall-st-jude-medical-riata-and-riata-st-silicone-endocardial-defibrillation-leads/</loc>
		<lastmod>2011-12-20T23:33:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 678: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/20/gilenya-fingolimod-drug-safety-communication/</loc>
		<lastmod>2011-12-20T23:33:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 677: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/20/fda-drug-safety-communication-review-update-of-multaq-dronedarone-and-increased-risk-of-death-and-serious-cardiovascular-adverse-events/</loc>
		<lastmod>2011-12-20T04:47:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 676: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/19/summary-information-for-atricure-synergy-ablation-system/</loc>
		<lastmod>2011-12-19T22:08:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 675: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/19/consumer-information-on-atricure-synergy-ablation-system/</loc>
		<lastmod>2011-12-19T22:08:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 674: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/16/draft-guidance-for-industry-and-food-and-drug-administration-staff-15/</loc>
		<lastmod>2011-12-16T20:50:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 673: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/15/fda-drug-safety-communication-revised-dose-limitation-for-zocor-simvastatin-when-taken-with-amiodarone/</loc>
		<lastmod>2011-12-16T02:23:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 672: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/15/selective-serotonin-reuptake-inhibitor-ssri-antidepressants-drug-safety-communication/</loc>
		<lastmod>2011-12-15T07:55:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 671: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/14/fda-drug-safety-communication-selective-serotonin-reuptake-inhibitor-ssri-antidepressant-use-during-pregnancy-and-reports-of-a-rare-heart-and-lung-condition-in-newborn-babies/</loc>
		<lastmod>2011-12-15T01:50:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 670: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/14/november-2011/</loc>
		<lastmod>2011-12-14T19:41:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 669: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/14/draft-guidance-for-industry-and-fda-staff-humanitarian-use-device-hud-designations/</loc>
		<lastmod>2011-12-14T07:34:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 668: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/13/gastric-banding/</loc>
		<lastmod>2011-12-13T18:39:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 667: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/12/fda-drug-safety-communication-safety-review-update-of-medications-used-to-treat-attention-deficithyperactivity-disorder-adhd-in-adults/</loc>
		<lastmod>2011-12-13T00:04:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 666: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/10/summary-information-for-promus-element-plus-everolimus-eluting-platinum-chromium-coronary-stent-system-monorail-and-over-the-wire/</loc>
		<lastmod>2011-12-10T16:04:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 665: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/10/consumer-information-on-promus-element-plus-everolimus-eluting-platinum-chromium-coronary-stent-system/</loc>
		<lastmod>2011-12-10T16:04:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 664: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/09/consumer-information-on-her2-cish-pharmdx-kit/</loc>
		<lastmod>2011-12-10T03:58:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 662: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/09/class-i-medical-device-recall-coopervision-avaira-toric-and-sphere-soft-contact-lenses/</loc>
		<lastmod>2011-12-10T03:58:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 663: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/09/summary-information-for-her2-cish-pharmdx-kit/</loc>
		<lastmod>2011-12-10T03:58:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 661: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/09/cord-blood-banking-information-for-consumers/</loc>
		<lastmod>2011-12-10T03:58:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 660: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/09/coopervision-avaira-toric-and-sphere-soft-contact-lenses-class-1-recall/</loc>
		<lastmod>2011-12-10T03:58:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 659: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/08/transcript-for-november-4-2011-national-mammography-quality-assurance-advisory-committee-meeting/</loc>
		<lastmod>2011-12-08T14:14:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 656: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/07/video-lasik-surgery-and-its-risks/</loc>
		<lastmod>2011-12-08T01:54:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 657: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/07/transcripts-for-october-26-27-2011-circulatory-system-devices-panel-of-the-medical-devices-advisory-committee-meeting/</loc>
		<lastmod>2011-12-08T01:54:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 658: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/07/fda-drug-safety-communication-safety-review-of-post-market-reports-of-serious-bleeding-events-with-the-anticoagulant-pradaxa-dabigatran-etexilate-mesylate/</loc>
		<lastmod>2011-12-08T01:54:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 655: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/07/class-i-medical-device-recall-coopervision-avaira-enfilcon-a-sphere-soft-contact-lenses/</loc>
		<lastmod>2011-12-08T01:54:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 654: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/07/coopervision-avaira-enfilcon-a-sphere-soft-contact-lens-class-1-recall/</loc>
		<lastmod>2011-12-08T01:54:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 653: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/07/pradaxa-dabigatran-etexilate-mesylate-drug-safety-communication-safety-review-of-post/</loc>
		<lastmod>2011-12-08T01:54:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 652: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/06/fda-drug-safety-communication-modified-risk-evaluation-and-mitigation-strategies-rems-for-nplate-romiplostim-and-promacta-eltrombopag/</loc>
		<lastmod>2011-12-07T01:31:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 651: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/06/transcript-for-october-13-2011-circulatory-system-devices-panel-of-the-medical-devices-advisory-committee/</loc>
		<lastmod>2011-12-07T01:31:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 650: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/06/class-i-medical-device-recall-draeger-medical-inc-infinity-acute-care-system-monitoring-solution-m540/</loc>
		<lastmod>2011-12-07T01:31:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 649: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/05/meeting-materials-for-december-7-8-2011-circulatory-system-devices-panel-of-the-medical-devices-advisory-committee/</loc>
		<lastmod>2011-12-06T00:12:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 648: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/05/notice-of-cancellation-of-meeting-december-14-2011-medical-devices-dispute-resolution-panel-of-the-medical-devices-advisory-committee/</loc>
		<lastmod>2011-12-05T10:55:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 647: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/02/cord-blood-banking-a%c2%a2a%e2%80%9a%c2%acaeoe-information-for-consumers/</loc>
		<lastmod>2011-12-02T19:37:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 646: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/01/draft-guidance-for-industry-and-food-and-drug-administration-staff-14/</loc>
		<lastmod>2011-12-01T18:45:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 645: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/01/updated-information-on-artificial-pancreas-systems/</loc>
		<lastmod>2011-12-01T18:45:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 644: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/30/pma-final-decisions-for-october-2011/</loc>
		<lastmod>2011-11-30T18:05:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 643: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/29/guidance-for-industry-and-food-and-drug-administration-staff-4/</loc>
		<lastmod>2011-11-29T04:51:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 642: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/25/october-2011/</loc>
		<lastmod>2011-11-26T01:30:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 641: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/23/consumer-information-on-neurx-dps-diaphragm-pacing-system/</loc>
		<lastmod>2011-11-23T22:47:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 640: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/23/summary-information-for-neurx-dps-diaphragm-pacing-system/</loc>
		<lastmod>2011-11-23T22:47:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 639: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/23/consumer-information-on-melafind/</loc>
		<lastmod>2011-11-23T10:11:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 638: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/23/summary-information-for-edwards-sapien-transcatheter-heart-valve/</loc>
		<lastmod>2011-11-23T10:11:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 637: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/22/consumer-information-on-edwards-sapien-transcatheter-heart-valve-thv/</loc>
		<lastmod>2011-11-22T21:56:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 636: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/22/consumer-information-on-belotero-balance/</loc>
		<lastmod>2011-11-22T21:56:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 635: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/22/summary-information-for-belotero-balance/</loc>
		<lastmod>2011-11-22T21:56:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 634: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/21/abbott-prism-chagas/</loc>
		<lastmod>2011-11-21T21:16:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 633: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/18/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-september-13-2011/</loc>
		<lastmod>2011-11-18T17:10:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 632: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/17/minutes-from-stakeholder-meeting-on-mdufa-iii-reauthorization-october-13-2011/</loc>
		<lastmod>2011-11-17T16:54:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 631: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/17/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-october-26-2011/</loc>
		<lastmod>2011-11-17T16:54:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 630: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/16/class-i-medical-device-recall-king-international-llc-shoulderemflex-emdeep-kneading-shiatsu-massager/</loc>
		<lastmod>2011-11-17T03:56:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 629: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/16/meeting-announcement-february-10-2012-neurological-devices-panel-of-the-medical-devices-advisory-committee/</loc>
		<lastmod>2011-11-16T15:43:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 628: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/14/virility-max-recall/</loc>
		<lastmod>2011-11-15T02:30:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 627: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/10/sop-decision-authority-for-additional-or-changed-data-needs-for-premarket-submissions/</loc>
		<lastmod>2011-11-10T23:05:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 626: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/10/draft-guidance-for-industry-clinical-investigators-institutional-review-boards-and-food-and-drug-administration-staff/</loc>
		<lastmod>2011-11-10T23:05:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 625: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/10/draft-guidance-for-industry-and-food-and-drug-administration-staff-13/</loc>
		<lastmod>2011-11-10T23:05:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 624: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/09/class-i-medical-device-recall-mizuho-osi-modular-table-systems/</loc>
		<lastmod>2011-11-09T22:25:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 623: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/09/trilipix-fenofibric-acid-drug-safety-communication/</loc>
		<lastmod>2011-11-09T22:25:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 622: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/09/mizuho-osi-modular-table-systems-class-i-recall/</loc>
		<lastmod>2011-11-09T22:25:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 621: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/08/needles-and-other-sharps-safe-disposal-outside-of-health-care-settings/</loc>
		<lastmod>2011-11-08T21:29:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 620: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/07/public-workshop-4/</loc>
		<lastmod>2011-11-07T21:11:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 619: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/07/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-october-21-2011/</loc>
		<lastmod>2011-11-07T21:11:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 618: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/07/draft-guidance-for-industry-and-food-and-drug-administration-staff-12/</loc>
		<lastmod>2011-11-07T21:11:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 617: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/06/summary-information-for-xience-prime-and-xience-prime-ll-everolimus-eluting-coronary-stent-system/</loc>
		<lastmod>2011-11-06T07:52:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 616: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/05/consumer-information-on-xience-prime-and-xience-prime-ll-everolimus-eluting-coronary-stent-system/</loc>
		<lastmod>2011-11-05T19:43:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 615: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/05/global-harmonization-task-force-new-international-medical-device-regulators-forum-statement-and-announcement-of-first-meeting/</loc>
		<lastmod>2011-11-05T19:43:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 614: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/05/consumer-information-on-elecsys-anti-hbc-igm-immunoassay-and-elecsys-precicontrol-anti-hbc-igm-on-the-cobas-e-601-analyzer/</loc>
		<lastmod>2011-11-05T19:43:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 613: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/05/summary-information-for-elecsys-anti-hbc-igm-immunoassay-and-elecsys-precicontrol-anti-hbc-igm/</loc>
		<lastmod>2011-11-05T07:35:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 612: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/05/class-i-medical-device-recall-carefusion-enve-ventilators/</loc>
		<lastmod>2011-11-05T07:35:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 611: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/05/summary-information-for-assurant-cobalt-iliac-balloon-expandable-stent-system/</loc>
		<lastmod>2011-11-05T07:35:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 610: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/04/fda-drug-safety-communication-reminder-to-healthcare-providers-and-patients-to-enroll-in-the-avandia-rosiglitazone-medicines-access-program/</loc>
		<lastmod>2011-11-05T01:31:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 609: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/04/consumer-information-on-assurant-cobalt-iliac-balloon-expandable-stent-system/</loc>
		<lastmod>2011-11-04T19:26:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 608: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/04/consumer-information-on-aptima-hpv-assay/</loc>
		<lastmod>2011-11-04T19:26:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 607: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/04/summary-information-for-aptima-hpv-assay/</loc>
		<lastmod>2011-11-04T19:26:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 606: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/04/carefusion-enve-ventilators-class-i-recall/</loc>
		<lastmod>2011-11-04T19:26:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 605: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/03/fda-drug-safety-communication-update-on-tumor-necrosis-factor-tnf-blockers-and-risk-for-pediatric-malignancy/</loc>
		<lastmod>2011-11-04T01:18:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 604: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/02/meeting-materials-for-national-mammography-quality-assurance-advisory-committee-meeting-on-november-4-2011/</loc>
		<lastmod>2011-11-02T18:55:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 603: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/02/public-workshop-3/</loc>
		<lastmod>2011-11-02T06:40:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 602: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/01/fda-drug-safety-communication-safety-review-update-of-medications-used-to-treat-attention-deficithyperactivity-disorder-adhd-in-children-and-young-adults/</loc>
		<lastmod>2011-11-02T00:33:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 601: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/31/understanding-barriers-to-medical-device-quality/</loc>
		<lastmod>2011-10-31T17:45:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 600: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/31/new-searchable-database-for-premarket-approval-pma-summary-review-memos-for-180-day-design-changes/</loc>
		<lastmod>2011-10-31T17:45:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 599: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/28/opportunities-for-collaboration/</loc>
		<lastmod>2011-10-28T21:15:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 598: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/27/fda-drug-safety-communication-updated-information-about-the-fda-funded-study-on-risk-of-blood-clots-in-women-taking-birth-control-pills-containing-drospirenone/</loc>
		<lastmod>2011-10-27T20:53:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 597: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/26/pma-final-decisions-for-september-2011/</loc>
		<lastmod>2011-10-27T02:25:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 596: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/26/information-for-health-care-professionals-anticipated-short-supply-of-coral-snake-antivenom-pfizer-inc/</loc>
		<lastmod>2011-10-27T02:25:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 595: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/26/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-reacciones-graves-en-el-sistema-nervioso-central-snc-cuando-se-administra-linezolid-zyvox-a-pacientes-que-toman-ciertos-medicamentos-p/</loc>
		<lastmod>2011-10-26T20:24:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 594: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/25/xigris-drotrecogin-alfa-activated-market-withdrawal/</loc>
		<lastmod>2011-10-26T01:52:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 593: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/24/biologics-sentinel-initiative-projects/</loc>
		<lastmod>2011-10-25T00:55:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 592: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/24/chantix-varenicline/</loc>
		<lastmod>2011-10-25T00:55:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 591: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/24/fda-drug-safety-communication-safety-review-update-of-chantix-varenicline-and-risk-of-neuropsychiatric-adverse-events/</loc>
		<lastmod>2011-10-24T18:25:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 590: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/22/consumer-information-on-restylane-injectable-gel/</loc>
		<lastmod>2011-10-22T11:25:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 589: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/summary-information-for-restylane-injectable-gel/</loc>
		<lastmod>2011-10-21T23:10:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 588: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/notice-of-postponement-of-meeting-december-1-2011-general-and-plastic-surgery-devices-panel-of-the-medical-devices-advisory-committee/</loc>
		<lastmod>2011-10-21T23:10:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 587: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/fda-communication-on-use-of-jet-injectors-with-influenza-vaccines/</loc>
		<lastmod>2011-10-21T23:10:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 586: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/nostrilla-nasal-decongestant-recall/</loc>
		<lastmod>2011-10-21T23:10:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 585: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/consumer-information-on-legoo/</loc>
		<lastmod>2011-10-21T10:30:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 584: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/summary-information-for-legoo/</loc>
		<lastmod>2011-10-21T10:30:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 583: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/consumer-information-on-euflexxa/</loc>
		<lastmod>2011-10-21T10:30:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 582: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/fda-drug-safety-communication-updated-information-about-the-drug-interaction-between-linezolid-zyvox-and-serotonergic-psychiatric-medications/</loc>
		<lastmod>2011-10-21T04:11:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 581: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/21/fda-drug-safety-communication-updated-information-about-the-drug-interaction-between-methylene-blue-methylthioninium-chloride-and-serotonergic-psychiatric-medications/</loc>
		<lastmod>2011-10-21T04:11:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 578: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/20/summary-information-for-advia-centaur-hbeag-assay-and-advia-centaur-hbeag-quality-control-material/</loc>
		<lastmod>2011-10-20T22:11:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 579: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/20/consumer-information-on-advia-centaur-hbeag-assay-and-advia-centaur-hbeag-quality-control-material/</loc>
		<lastmod>2011-10-20T22:11:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 580: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/20/summary-information-for-euflexxa/</loc>
		<lastmod>2011-10-20T22:11:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 577: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/19/medical-device-pre-market-programs-an-overview-of-fda-actions/</loc>
		<lastmod>2011-10-19T21:34:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 576: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/19/accomplishments-cdrh-plan-of-action-for-510k-and-science/</loc>
		<lastmod>2011-10-19T21:34:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 575: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/17/letter-to-manufacturers-concerning-sids-prevention-medical-claims-for-baby-products/</loc>
		<lastmod>2011-10-17T20:12:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 574: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/17/draft-guidance-for-industry-and-food-and-drug-administration-staff-11/</loc>
		<lastmod>2011-10-17T20:12:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 573: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/17/information-on-baby-products-with-sids-prevention-claims/</loc>
		<lastmod>2011-10-17T20:12:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 572: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/15/15th-annual-report-to-congress-on-the-performance-of-accreditation-bodies-under-mqsa-pdf/</loc>
		<lastmod>2011-10-15T18:57:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 571: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/15/class-i-medical-device-recall-coopervision-avaira-toric-soft-contact-lenses/</loc>
		<lastmod>2011-10-15T05:35:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 570: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/15/coopervision-avaira-toric-soft-contact-lenses-class-1-recall-unintended-residue-on-lenses/</loc>
		<lastmod>2011-10-15T05:35:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 569: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/14/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-informes-sobre-un-efecto-adverso-raro-pero-grave-y-potencialmente-fatal-del-uso-de-benzocana-en-gel-o-lquido-de-venta-libre-q/</loc>
		<lastmod>2011-10-14T23:33:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 568: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/14/preventing-surgical-fires/</loc>
		<lastmod>2011-10-14T23:33:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 567: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/14/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-contina-la-revisin-sobre-la-seguridad-de-los-medicamentos-para-la-osteoporosis-bifosfonatos-por-va-oral-en-relaci/</loc>
		<lastmod>2011-10-14T11:00:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 566: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/14/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-posibles-reacciones-graves-en-el-snc-cuando-se-administra-azul-de-metileno-a-pacientes-que-toman-ciertos-medicamentos-psiquitricos/</loc>
		<lastmod>2011-10-14T11:00:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 565: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/14/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-actualizacin-de-la-revisin-de-seguridad-de-la-hormona-de-crecimiento-humana-recombinante-somatropina-y-su-posible-aumento/</loc>
		<lastmod>2011-10-14T11:00:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 563: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/13/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-ritmos-cardacos-anormales-asociados-con-dosis-altas-de-celexa-bromhidrato-de-citalopram/</loc>
		<lastmod>2011-10-13T22:46:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 564: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/13/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-actualizacin-de-las-etiquetas-de-los-medicamentos-que-contienen-pioglitazona/</loc>
		<lastmod>2011-10-13T22:46:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 562: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/13/comunicado-de-la-fda-sobre-la-seguridad-de-los-medicamentos-la-etiqueta-del-medicamento-chantix-vareniclina-ahora-contiene-informacin-actualizada-sobre-su-eficacia-y-seguridad/</loc>
		<lastmod>2011-10-13T22:46:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 561: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/13/minutes-from-stakeholder-meeting-on-mdufa-iii-reauthorization-september-6-2011/</loc>
		<lastmod>2011-10-13T16:42:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 560: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/13/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-august-31-2011/</loc>
		<lastmod>2011-10-13T16:42:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 559: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/13/fda-safety-communication-preventing-surgical-fires/</loc>
		<lastmod>2011-10-13T16:42:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 558: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/12/decorative-contact-lenses/</loc>
		<lastmod>2011-10-12T16:03:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 557: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/11/fda-drug-safety-communication-sprycel-dasatinib-and-risk-of-pulmonary-arterial-hypertension/</loc>
		<lastmod>2011-10-11T21:19:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 556: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/11/sprycel-dasatinib-drug-safety-communication/</loc>
		<lastmod>2011-10-11T15:16:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 555: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/07/fda-cms-parallel-review/</loc>
		<lastmod>2011-10-07T19:56:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 554: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/07/uprizing-2-0-recall/</loc>
		<lastmod>2011-10-07T07:33:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 553: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/06/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-august-24-2011/</loc>
		<lastmod>2011-10-06T18:28:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 552: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/05/phase-out-of-albuterol-cfc-metered-dose-inhalers/</loc>
		<lastmod>2011-10-05T22:57:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 551: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/05/hizentra/</loc>
		<lastmod>2011-10-05T16:55:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 550: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/04/network-of-experts-expert-utilization-standard-operating-procedure-draft/</loc>
		<lastmod>2011-10-05T03:54:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 549: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/04/network-of-experts-expert-enrollment-standard-operating-procedure-draft/</loc>
		<lastmod>2011-10-05T03:54:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 548: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/04/regulatory-science-in-fdas-center-for-devices-and-radiological-health-a-vital-framework-for-protecting-and-promoting-public-health-pdf/</loc>
		<lastmod>2011-10-04T15:41:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 547: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/03/information-on-denture-adhesives/</loc>
		<lastmod>2011-10-04T01:47:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 546: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/03/class-i-medical-device-recall-lee-medical-international-inc-custom-dialysis-trays-kits/</loc>
		<lastmod>2011-10-03T13:40:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 545: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/30/draft-guidance-for-industry-and-food-and-drug-administration-staff-10/</loc>
		<lastmod>2011-09-30T22:46:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 544: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/29/documents-the-center-for-devices-and-radiological-health-is-considering-for-development-fy12/</loc>
		<lastmod>2011-09-29T22:04:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 543: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/28/pma-final-decisions-for-july-2011/</loc>
		<lastmod>2011-09-28T20:28:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 542: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/28/pma-final-decisions-for-august-2011/</loc>
		<lastmod>2011-09-28T20:28:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 541: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/27/twinrix/</loc>
		<lastmod>2011-09-27T19:06:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 540: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/26/fda-drug-safety-communication-safety-review-update-on-the-possible-increased-risk-of-blood-clots-with-birth-control-pills-containing-drospirenone/</loc>
		<lastmod>2011-09-27T00:42:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 539: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/26/questions-and-answers/</loc>
		<lastmod>2011-09-27T00:42:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 538: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/21/minutes-from-stakeholder-meeting-on-mdufa-iii-reauthorization-august-18-2011/</loc>
		<lastmod>2011-09-21T17:13:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 537: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/21/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-august-9-2011/</loc>
		<lastmod>2011-09-21T17:13:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 536: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/20/stay-informed-about-small-business/</loc>
		<lastmod>2011-09-20T23:02:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 535: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/20/public-workshop-magnetic-resonance-imaging-safety-october-25-26-2011/</loc>
		<lastmod>2011-09-20T16:18:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 534: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/19/advisory-committee-notice-of-meeting-october-26-27-2011/</loc>
		<lastmod>2011-09-19T15:32:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 533: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/19/august-2011/</loc>
		<lastmod>2011-09-19T15:32:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 532: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/16/class-i-medical-device-recall-lee-medical-international-inc-custom-dialysis-trayskits/</loc>
		<lastmod>2011-09-17T02:10:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 531: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/16/qualitest-pharmaceuticals-oral-contraceptives-recall/</loc>
		<lastmod>2011-09-17T02:10:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 530: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/15/zofran-ondansetron-drug-safety-communication/</loc>
		<lastmod>2011-09-16T01:20:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 529: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/14/24-hour-summary-for-the-obstetrics-and-gynecology-devices-panel-meeting-held-on-september-8-9-2011/</loc>
		<lastmod>2011-09-15T01:08:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 528: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/13/comunicado-de-seguridad-de-medicamentos-de-la-fda-ritmos-cardacos-anormales-asociados-con-dosis-altas-de-celexa-bromhidrato-de-citalopram/</loc>
		<lastmod>2011-09-13T06:12:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 527: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/12/class-i-medical-device-recall-medtronic-model-8637-synchromed-ii-implantable-infusion-pump/</loc>
		<lastmod>2011-09-13T00:12:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 526: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/12/medtronic-model-8637-synchromed-ii-implantable-infusion-pump-class-i-recall/</loc>
		<lastmod>2011-09-13T00:12:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 525: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/12/advisory-committee-notice-of-meeting-october-13-2011/</loc>
		<lastmod>2011-09-12T12:05:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 524: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/10/statement-from-fda-commissioner-margaret-hamburg-m-d-and-assistant-secretary-for-health-howard-koh-m-d-m-p-h-on-drug-shortages/</loc>
		<lastmod>2011-09-10T04:31:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 523: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/09/meeting-materials-for-the-obstetrics-and-gynecology-devices-panel-meeting-held-on-september-8-9-2011/</loc>
		<lastmod>2011-09-09T22:10:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 522: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/08/letter-to-industry-about-import-entry-review-process-september-6-2011/</loc>
		<lastmod>2011-09-08T21:58:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 521: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/08/tumor-necrosis-factor-alpha-tnf-blockers-label-change/</loc>
		<lastmod>2011-09-08T09:53:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 520: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/07/fda-drug-safety-communication-drug-labels-for-the-tumor-necrosis-factor-alpha-tnf-blockers-now-include-warnings-about-infection-with-legionella-and-listeria-bacteria/</loc>
		<lastmod>2011-09-08T03:49:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 519: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/07/summary-information-for-vysis-alk-break-apart-fish-probe-kit-vysis-paraffin-pretreatment-iv-and-post-hybridization-wash-buffer-kit-probechek-alk-negative-control-slides-and-probechek-alk-positive/</loc>
		<lastmod>2011-09-07T09:27:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 518: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/06/consumer-information-on-vysis-alk-break-apart-fish-probe-kit-with-the-vysis-paraffin-pretreatment-iv-and-post-hybridization-wash-buffer-kit-probechek-alk-negative-control-slides-and-probechek-alk/</loc>
		<lastmod>2011-09-06T21:19:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 517: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/06/fda-safety-communication-update-on-life-threatening-injuries-associated-with-the-shoulderflex-massager/</loc>
		<lastmod>2011-09-06T21:19:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 516: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/06/safety-article-take-precautions-with-audible-alarms-on-ventilators/</loc>
		<lastmod>2011-09-06T21:19:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 515: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/03/manufacturer-evaluation-codes/</loc>
		<lastmod>2011-09-03T08:00:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 514: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/03/cdrh-learn-spanish-overview-of-regulatory-requirements-medical-devices/</loc>
		<lastmod>2011-09-03T08:00:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 513: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/02/tachosil/</loc>
		<lastmod>2011-09-02T19:45:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 511: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/02/saphris-asenapine-maleate-drug-safety-communication-serious-allergic-reactions/</loc>
		<lastmod>2011-09-02T07:11:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 512: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/02/reclast-zoledronic-acid-drug-safety-communication/</loc>
		<lastmod>2011-09-02T07:11:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 510: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/01/fda-drug-safety-communication-new-contraindication-and-updated-warning-on-kidney-impairment-for-reclast-zoledronic-acid/</loc>
		<lastmod>2011-09-02T01:11:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 509: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/01/fda-drug-safety-communication-serious-allergic-reactions-reported-with-the-use-of-saphris-asenapine-maleate/</loc>
		<lastmod>2011-09-02T01:11:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 508: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/31/cdrh-learn-spanish-510k-third-party-review-online-video-presentation-and-printable-slide-presentation/</loc>
		<lastmod>2011-08-31T06:27:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 507: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/30/fda-alerts-health-care-professionals-of-infection-risk-from-repackaged-avastin-intravitreal-injections/</loc>
		<lastmod>2011-08-31T00:15:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 506: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/29/draft-guidance-for-industry-on-oversight-of-clinical-investigations-a-risk-based-approach-to-monitoring/</loc>
		<lastmod>2011-08-29T17:57:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 505: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/26/shoulderflex-massager-by-king-international-safety-communication/</loc>
		<lastmod>2011-08-26T16:17:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 504: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/26/h-p-industries-povidone-iodine-swabsticks-prep-solutions-scrub-solutions-and-prep-gel-recall/</loc>
		<lastmod>2011-08-26T16:17:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 503: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/25/life-threatening-injuries-associated-with-the-shoulderflex-massager/</loc>
		<lastmod>2011-08-26T02:50:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 502: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/24/novosevenrt/</loc>
		<lastmod>2011-08-25T02:17:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 501: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/24/fda-drug-safety-communication-abnormal-heart-rhythms-associated-with-high-doses-of-celexa-citalopram-hydrobromide/</loc>
		<lastmod>2011-08-24T20:10:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 500: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/24/celexa-citalopram-hydrobromide-drug-safety-communication/</loc>
		<lastmod>2011-08-24T13:54:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 499: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/23/kogenate-fs/</loc>
		<lastmod>2011-08-24T01:43:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 498: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/23/comunicado-de-seguridad-de-medicamentos-de-la-fda-informes-sobre-un-efecto-adverso-raro-pero-grave-y-potencialmente-fatal-del-uso-de-benzocana-en-gel-o-lquido-de-venta-libre-que-se-apli/</loc>
		<lastmod>2011-08-23T19:41:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 497: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/22/two-day-tissue-adhesives-soft-tissue-workshop-symposium-september-26-27-2011/</loc>
		<lastmod>2011-08-23T00:41:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 496: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/20/summary-information-for-propel/</loc>
		<lastmod>2011-08-20T10:31:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 495: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/19/consumer-information-on-propel/</loc>
		<lastmod>2011-08-19T22:01:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 494: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/19/consumer-information-on-cobas-4800-braf-v600-mutation-test/</loc>
		<lastmod>2011-08-19T22:01:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 493: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/19/summary-information-for-cobas-4800-braf-v600-mutation-test/</loc>
		<lastmod>2011-08-19T22:01:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 492: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/19/infanrix/</loc>
		<lastmod>2011-08-19T22:01:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 491: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/18/pma-final-decisions-for-june-2011/</loc>
		<lastmod>2011-08-18T21:20:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 490: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/18/engerix-b/</loc>
		<lastmod>2011-08-18T21:20:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 489: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/17/comunicado-de-seguridad-de-medicamentos-de-la-fda-actualizacion-de-las-etiquetas-de-los-medicamentos-que-contienen-pioglitazona/</loc>
		<lastmod>2011-08-18T02:55:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 488: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/17/comunicado-de-seguridad-de-medicamentos-de-la-fda-actualizacion-de-la-revision-de-seguridad-de-la-hormona-de-crecimiento-humana-recombinante-somatropina-y-su-posible-aumento-de-riesgo-de-muerte/</loc>
		<lastmod>2011-08-18T02:55:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 487: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/16/draft-guidance-for-industry-and-food-and-drug-administration-staff-9/</loc>
		<lastmod>2011-08-16T20:15:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 486: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/16/515-program-initiative-project-status-update-female-condom-pacemaker-repair-or-replacement-material-ventricular-bypass-assist-device/</loc>
		<lastmod>2011-08-16T20:15:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 485: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/15/drug-establishment-annual-registration-status-download-file/</loc>
		<lastmod>2011-08-16T01:44:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 484: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/15/draft-guidance-for-industry-clinical-investigators-and-food-and-drug-administration-staff/</loc>
		<lastmod>2011-08-15T19:44:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 483: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/15/draft-guidance-for-industry-and-food-and-drug-administration-staff-factors-to-consider-when-making-benefit/</loc>
		<lastmod>2011-08-15T19:44:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 482: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/15/cdrh-learn-medical-devices-in-the-home-presentations/</loc>
		<lastmod>2011-08-15T19:44:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 480: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/12/comunicado-de-seguridad-de-medicamentos-de-la-fda-reacciones-graves-en-el-sistema-nervioso-central-snc-cuando-se-administra-linezolid-zyvox-a-pacientes-que-toman-ciertos-medicamentos-psiquiaacu/</loc>
		<lastmod>2011-08-13T00:09:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 481: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/12/fda-drug-safety-communication-serious-cns-reactions-possible-when-linezolid-zyvox-is-given-to-patients-taking-certain-psychiatric-medications-2/</loc>
		<lastmod>2011-08-13T00:09:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 479: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/12/comunicado-de-seguridad-de-medicamentos-de-la-fda-posibles-reacciones-graves-en-el-snc-cuando-se-administra-azul-de-metileno-a-pacientes-que-toman-ciertos-medicamentos-psiquitricos/</loc>
		<lastmod>2011-08-13T00:09:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 478: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/12/public-workshop-mobile-medical-applications-draft-guidance-september-12/</loc>
		<lastmod>2011-08-12T17:54:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 477: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/12/public-meeting-2/</loc>
		<lastmod>2011-08-12T17:54:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 476: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/11/minutes-from-stakeholder-meeting-on-mdufa-iii-reauthorization-july-27-2011/</loc>
		<lastmod>2011-08-11T17:16:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 475: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/11/fda-nhlbi-nsf-workshop-on-computer-methods-for-medical-devices-validation-of-computer-with-nonclinical-models-september-7-9-2011/</loc>
		<lastmod>2011-08-11T17:16:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 473: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/10/important-information-on-the-medical-device-user-fee-rates-for-fy2012-updated/</loc>
		<lastmod>2011-08-10T04:24:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 474: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/10/public-meeting/</loc>
		<lastmod>2011-08-10T04:24:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 472: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/10/agenda-and-materials-from-the-july-26-2011-quarterly-meeting-on-mdufma-mdufa-performance-pdf/</loc>
		<lastmod>2011-08-10T04:24:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 471: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/09/guidance-for-industry-and-food-and-drug-administration-staff-3/</loc>
		<lastmod>2011-08-09T15:28:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 470: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/09/515-program-initiative-project-status-update-pacemaker-programmer-cardiovascular-permanent-pacemaker-electrode-cranial-electrotherapy-stimulator/</loc>
		<lastmod>2011-08-09T15:28:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 469: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/08/guidance-for-industry-and-food-and-drug-administration-staff-and-foreign-governments/</loc>
		<lastmod>2011-08-08T14:55:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 468: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/06/comunicado-de-seguridad-de-medicamentos-de-la-fda-la-etiqueta-del-medicamento-chantix-vareniclina-ahora-contiene-informacin-actualizada-de-eficacia-y-seguridad/</loc>
		<lastmod>2011-08-06T06:31:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 467: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/05/important-information-on-the-medical-device-user-fee-rates-for-fy2012/</loc>
		<lastmod>2011-08-06T00:27:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 466: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/05/safe-use-initiative-acetaminophen-toxicity/</loc>
		<lastmod>2011-08-05T05:54:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 465: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/05/fda-drug-safety-communication-updated-drug-labels-for-pioglitazone-containing-medicines/</loc>
		<lastmod>2011-08-05T05:54:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 464: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/04/vasopressin-injection-usp-multiple-dose-vials-recall-sub/</loc>
		<lastmod>2011-08-04T23:48:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 463: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/04/fda-drug-safety-communication-safety-review-update-of-recombinant-human-growth-hormone-somatropin-and-possible-increased-risk-of-death/</loc>
		<lastmod>2011-08-04T17:48:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 462: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/class-i-medical-device-recall-ge-healthcare-vital-signs-hygroscopic-condenser-humidifier-passive-humidification-device-hch-for-vital-signs-anesthesia-breathing-circuits/</loc>
		<lastmod>2011-08-03T22:59:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 461: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/class-i-medical-device-recall-arrow-international-inc-arrow-nextstep-antegrade-chronic-hemodialysis-catheter/</loc>
		<lastmod>2011-08-03T22:59:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 458: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/ge-healthcare-vital-signs-hygroscopic-condenser-humidifier-passive-humidification-device-hch-class-i-recall/</loc>
		<lastmod>2011-08-03T22:59:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 459: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/arrow-international-inc-arrow-nextstep-antegrade-chronic-hemodialysis-catheter-class-i-recall/</loc>
		<lastmod>2011-08-03T22:59:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 460: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/diflucan-fluconazole-drug-safety-communication-%e2%80%93-long-term-high-dose-use-during-pregnancy-may-be-associated-with-birth-defects/</loc>
		<lastmod>2011-08-03T22:59:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 457: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/fda-drug-safety-communicationuse-of-long-term-high-dose-diflucan-fluconazole-during-pregnancy-may-be-associated-with-birth-defects-in-infants/</loc>
		<lastmod>2011-08-03T16:57:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 456: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/comunicado-de-seguridad-de-medicamentos-de-la-fda-contina-la-revisin-de-seguridad-de-los-medicamentos-por-va-oral-para-la-osteoporosis-bifosfonatos-en-relacin-con-un-2/</loc>
		<lastmod>2011-08-03T04:53:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 455: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/03/comunicado-de-seguridad-de-medicamentos-de-la-fda-contina-la-revisin-de-seguridad-de-los-medicamentos-por-va-oral-para-la-osteoporosis-bifosfonatos-en-relacin-con-un/</loc>
		<lastmod>2011-08-03T04:53:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 454: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/02/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-july-15-2011/</loc>
		<lastmod>2011-08-02T22:38:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 453: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/02/consumer-information-on-vitros-immunodiagnostic-products-anti-hbe-reagent-pack-calibrator-and-controls/</loc>
		<lastmod>2011-08-02T10:21:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 452: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/02/summary-information-for-vitros-immunodiagnostic-products-anti-hbe-reagent-pack-vitros-immunodiagnostic-products-anti-hbe-calibrator-and-vitros-immunodiagnostic-products-anti-hbe-controls/</loc>
		<lastmod>2011-08-02T10:21:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 450: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/01/consumer-information-on-rx-herculink-elite-renal-stent-system/</loc>
		<lastmod>2011-08-01T22:09:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 451: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/01/summary-information-for-rx-herculink-elite-renal-stent-system/</loc>
		<lastmod>2011-08-01T22:09:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 449: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/01/class-i-medical-device-recall-gem-premier-4000-pak-cartridges-for-use-on-the-gem-premier-4000-system/</loc>
		<lastmod>2011-08-01T22:09:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 448: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/01/gem-premier-4000-pak-cartridges-for-use-on-the-gem-premier-4000-system-class-i-recall/</loc>
		<lastmod>2011-08-01T22:09:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 447: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/30/center-for-devices-and-radiological-health-guidance-development-sop/</loc>
		<lastmod>2011-07-30T08:42:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 446: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/30/cdrh-transparency-515-program-initiative-project-status-update/</loc>
		<lastmod>2011-07-30T08:42:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 445: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/30/cdrh-learn-global-harmonization-single-audit-program/</loc>
		<lastmod>2011-07-30T08:42:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 444: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/29/information-for-industry-x-ray-imaging-devices/</loc>
		<lastmod>2011-07-29T20:26:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 443: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/28/class-i-medical-device-recall-global-focus-marketing-distribution-ltd-silencer-s2200-centrifuge/</loc>
		<lastmod>2011-07-28T07:32:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 442: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/27/silencer-s2200-centrifuge-by-global-focus-marketing-distribution-ltd-class-i-recall/</loc>
		<lastmod>2011-07-27T19:03:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 441: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/27/zyvox-linezolid-drug-safety-communication/</loc>
		<lastmod>2011-07-27T06:35:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 440: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/27/methylene-blue-drug-safety-communication/</loc>
		<lastmod>2011-07-27T06:35:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 439: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/26/fda-drug-safety-communication-fda-alerts-healthcare-professionals-to-stop-performing-heart-scans-with-cardiogen-82-due-to-potential-for-increased-radiation-exposure-in-patients/</loc>
		<lastmod>2011-07-27T00:16:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 438: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/26/fda-drug-safety-communication-serious-cns-reactions-possible-when-methylene-blue-is-given-to-patients-taking-certain-psychiatric-medications/</loc>
		<lastmod>2011-07-27T00:16:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 437: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/26/fda-drug-safety-communication-serious-cns-reactions-possible-when-linezolid-zyvox-is-given-to-patients-taking-certain-psychiatric-medications/</loc>
		<lastmod>2011-07-27T00:16:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 436: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/26/guidance-for-industry-and-fda-staff-9/</loc>
		<lastmod>2011-07-26T18:09:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 435: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/26/guidance-for-industry-and-fda-staff-8/</loc>
		<lastmod>2011-07-26T18:09:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 434: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/26/cdrh-learn-bimo-part-5b/</loc>
		<lastmod>2011-07-26T18:09:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 433: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/25/fda-drug-safety-communication-chantix-varenicline-drug-label-now-contains-updated-efficacy-and-safety-information/</loc>
		<lastmod>2011-07-25T23:29:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 432: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/25/havrix/</loc>
		<lastmod>2011-07-25T17:24:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 431: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/21/oral-osteoporosis-drugs-bisphosphonates-drug-safety-communication/</loc>
		<lastmod>2011-07-22T03:06:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 430: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/21/multaq-dronedarone-drug-safety-communication/</loc>
		<lastmod>2011-07-22T03:06:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 429: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/21/inactive-ingredients-database-download/</loc>
		<lastmod>2011-07-21T21:05:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 428: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/21/fda-drug-safety-communication-ongoing-safety-review-of-oral-osteoporosis-drugs-bisphosphonates-and-potential-increased-risk-of-esophageal-cancer/</loc>
		<lastmod>2011-07-21T21:05:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 427: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/21/fda-drug-safety-communication-multaq-dronedarone-and-increased-risk-of-death-and-serious-cardiovascular-adverse-events/</loc>
		<lastmod>2011-07-21T21:05:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 426: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/21/unique-device-identification-udi-for-postmarket-surveillance-and-enforcement-public-workshop-september-12-13-2011/</loc>
		<lastmod>2011-07-21T15:05:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 425: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/21/guidance-for-industry-and-food-and-drug-administration-staff-2/</loc>
		<lastmod>2011-07-21T15:05:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 424: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/20/mammography-facility-adverse-event-and-action-report/</loc>
		<lastmod>2011-07-21T02:57:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 423: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/20/guidance-for-industry-and-fda-staff-7/</loc>
		<lastmod>2011-07-21T02:57:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 422: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/20/june-2011/</loc>
		<lastmod>2011-07-20T13:31:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 421: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/19/information-on-mobile-medical-applications/</loc>
		<lastmod>2011-07-20T01:21:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 420: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/19/draft-guidance-for-industry-and-food-and-drug-administration-staff-8/</loc>
		<lastmod>2011-07-20T01:21:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 419: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/19/analysis-of-premarket-review-times-under-the-510k-program/</loc>
		<lastmod>2011-07-20T01:21:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 418: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/18/afluria/</loc>
		<lastmod>2011-07-19T00:39:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 417: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/18/cardiogen-82-pet-scan-drug-safety-communication/</loc>
		<lastmod>2011-07-19T00:39:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 416: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/17/update-on-the-safety-of-silicone-gel-filled-breast-implants/</loc>
		<lastmod>2011-07-17T11:32:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 415: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/17/information-on-breast-implants/</loc>
		<lastmod>2011-07-17T11:32:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 414: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/17/video-2/</loc>
		<lastmod>2011-07-17T11:32:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 413: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/video/</loc>
		<lastmod>2011-07-16T23:13:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 412: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/minutes-from-stakeholder-meeting-on-mdufa-iii-reauthorization-june-16-2011/</loc>
		<lastmod>2011-07-16T23:13:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 411: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/summary-information-for-elecsys-anti-hbc-immunoassay-and-elecsys-precicontrol-anti-hbc-on-the-elecsys-2010-immunoassay-analyzer/</loc>
		<lastmod>2011-07-16T23:13:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 410: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/town-hall-discussion-with-the-director-of-cdrh-and-other-senior-center-management-september-22-2011/</loc>
		<lastmod>2011-07-16T10:26:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 409: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/federal-register-town-hall-discussion-with-the-director-of-cdrh-and-other-senior-center-management-september-22-2011/</loc>
		<lastmod>2011-07-16T10:26:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 408: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/pma-final-decisions-for-may-2011/</loc>
		<lastmod>2011-07-16T10:26:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 407: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/transvaginal-placement-of-surgical-mesh/</loc>
		<lastmod>2011-07-16T10:26:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 405: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/fda-drug-safety-communication-increased-radiation-exposure-due-to-undetected-strontium-breakthrough-when-using-cardiogen-82-for-cardiac-positron-emission-tomography-pet-scans/</loc>
		<lastmod>2011-07-16T04:13:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 406: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/16/adverse-event-reporting-system-aers-statistics/</loc>
		<lastmod>2011-07-16T04:13:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 404: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/15/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-june-27-2011/</loc>
		<lastmod>2011-07-15T21:47:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 403: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/15/guidance-for-industry-and-fda-staff-6/</loc>
		<lastmod>2011-07-15T21:47:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 402: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/15/center-for-devices-and-radiological-health-forum-for-international-medical-device-regulatory-authorities-advanced-session-september-13-16-2011/</loc>
		<lastmod>2011-07-15T21:47:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 401: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/15/consumer-information-on-elecsys-anti-hbc-immunoassay-and-elecsys-precicontrol-anti-hbc-on-the-elecsys-2010-immunoassay-analyzer/</loc>
		<lastmod>2011-07-15T08:59:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 400: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/15/consumer-information-on-elecsys-anti-hbc-immunoassay-and-elecsys-precicontrol-anti-hbc-for-use-on-the-e170-modular-analytics/</loc>
		<lastmod>2011-07-15T08:59:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 399: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/15/urogynecologic-surgical-mesh-update-on-the-safety-and-effectiveness-of-transvaginal-placement-for-pelvic-organ-prolapse-july-2011-pdf/</loc>
		<lastmod>2011-07-15T08:59:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 398: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/information-on-urogynecologic-surgical-mesh-implants/</loc>
		<lastmod>2011-07-14T20:29:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 397: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/fda-safety-communication-update-on-serious-complications-associated-with-transvaginal-placement-of-surgical-mesh-for-pelvic-organ-prolapse/</loc>
		<lastmod>2011-07-14T20:29:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 396: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/cdrh-learn-new-course-available-2/</loc>
		<lastmod>2011-07-14T20:29:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 395: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/summary-information-for-elecsys-anti-hbc-immunoassay-and-elecsys-precicontrol-anti-hbc-for-use-on-the-e170-modular-analytics/</loc>
		<lastmod>2011-07-14T08:14:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 394: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-june-17-2011/</loc>
		<lastmod>2011-07-14T08:14:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 393: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/draft-guidance-for-industry-and-food-and-drug-administration-staff-7/</loc>
		<lastmod>2011-07-14T08:14:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 391: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/biologic-product-shortages/</loc>
		<lastmod>2011-07-14T08:14:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 392: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/14/influenza-virus-vaccine-for-the-2011/</loc>
		<lastmod>2011-07-14T08:14:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 390: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/13/evaluation-of-automatic-class-iii-designation-de-novo-decision-summary-k093937/</loc>
		<lastmod>2011-07-13T05:22:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 389: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/13/federal-register-draft-guidance-for-industry-and-food-and-drug-administration-staff-enforcement-policy-for-premarket-notification-requirements-for-certain-in-vitro-diagnostic-and-radiology-devices/</loc>
		<lastmod>2011-07-13T05:22:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 388: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/13/draft-guidance-for-industry-and-food-and-drug-administration-staff-6/</loc>
		<lastmod>2011-07-13T05:22:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 387: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/11/tamiflu-oseltamivir-phosphate-for-oral-suspension-label-change-new-concentration-6-mgml/</loc>
		<lastmod>2011-07-11T22:10:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 385: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/09/slim-forte-slimming-capsule-and-slim-forte-double-power-slimming-capsules-public-notification/</loc>
		<lastmod>2011-07-09T06:47:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 386: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/09/slim-forte-slimming-capsules-slim-forte-slimming-coffee-and-botanical-slimming-soft-gel-public-notification/</loc>
		<lastmod>2011-07-09T06:47:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 384: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/08/nulojix-belatacept-risk-evaluation-and-mitigation-strategy-rems/</loc>
		<lastmod>2011-07-08T05:31:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 383: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/05/fluarix/</loc>
		<lastmod>2011-07-05T14:57:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 382: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/30/valproate-products-drug-safety-communication/</loc>
		<lastmod>2011-06-30T21:41:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 381: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/30/fda-drug-safety-communication-children-born-to-mothers-who-took-valproate-products-while-pregnant-may-have-impaired-cognitive-development/</loc>
		<lastmod>2011-06-30T21:41:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 380: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/30/tylenol-extra-strength-caplets-225-count-bottles-recall/</loc>
		<lastmod>2011-06-30T09:23:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 379: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/29/drug-firm-annual-registration-status-download-file/</loc>
		<lastmod>2011-06-29T21:17:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 378: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/29/breakdown-of-fdaaa-completed-pediatric-studies/</loc>
		<lastmod>2011-06-29T21:17:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 377: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/28/list-of-establishments-granted-approval-for-a-variance-to-21cfr640-3d-and-21cfr640-3f/</loc>
		<lastmod>2011-06-28T20:46:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 376: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/28/exceptions-and-alternative-procedures-approved-under-21-cfr-640-120/</loc>
		<lastmod>2011-06-28T20:46:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 373: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/27/nature-relief-instant-wart-and-mole-remover-recall/</loc>
		<lastmod>2011-06-27T19:49:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 374: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/27/endocet-oxycodone-acetaminophen-tablets-10mg-325mg-recall/</loc>
		<lastmod>2011-06-27T19:49:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 375: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/27/butalbital-acetaminophen-and-caffeine-tablets-usp-50mg-325mg-40mg-and-hydrocodone-bitartrate-and-acetaminophen-tablets-usp-7-5mg-500mg-recall/</loc>
		<lastmod>2011-06-27T19:49:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 372: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/25/fda-drug-safety-communication-modified-dosing-recommendations-to-improve-the-safe-use-of-erythropoiesis-stimulating-agents-esas-in-chronic-kidney-disease/</loc>
		<lastmod>2011-06-25T04:29:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 371: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/24/erythropoiesis-stimulating-agents-esas-in-chronic-kidney-disease-drug-safety-communication/</loc>
		<lastmod>2011-06-24T16:03:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 370: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/23/fda-update-on-the-safety-of-silicone-gel-filled-breast-implants-pdf/</loc>
		<lastmod>2011-06-23T14:41:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 369: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/23/booklet/</loc>
		<lastmod>2011-06-23T14:41:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 368: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/23/anaplastic-large-cell-lymphoma-alcl/</loc>
		<lastmod>2011-06-23T14:41:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 367: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/22/draft-guidance-for-industry-and-food-and-drug-administration-staff-5/</loc>
		<lastmod>2011-06-23T02:06:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 366: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/21/minutes-from-negotiation-meeting-on-mdufa-iii-reauthorization-june-1-2011/</loc>
		<lastmod>2011-06-21T12:45:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 365: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/20/class-i-medical-device-recall-roche-diagnostics-operations-accu-chek-performa-strip/</loc>
		<lastmod>2011-06-21T00:35:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 364: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/20/draft-guidance-for-industry-and-food-and-drug-administration-staff-4/</loc>
		<lastmod>2011-06-21T00:35:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 363: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/20/information-on-artificial-pancreas-systems/</loc>
		<lastmod>2011-06-21T00:35:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 362: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/20/risperdal-risperidone-and-risperidone-recall/</loc>
		<lastmod>2011-06-21T00:35:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 361: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/17/fy-2010-osel-annual-report/</loc>
		<lastmod>2011-06-17T20:02:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 360: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/17/boston-scientific-innova-self-expanding-stent-system-recall/</loc>
		<lastmod>2011-06-17T20:01:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 359: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/17/orange-book-current-cumulative-supplement/</loc>
		<lastmod>2011-06-17T20:01:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 358: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/17/summary-information-for-solesta/</loc>
		<lastmod>2011-06-17T07:36:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 357: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/17/consumer-information-on-solesta/</loc>
		<lastmod>2011-06-17T07:36:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 356: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/17/chantix-varenicline-label-change/</loc>
		<lastmod>2011-06-17T07:36:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 355: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/summary-information-for-pinnacle-complete-acetabular-hip-system/</loc>
		<lastmod>2011-06-16T19:23:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 354: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/consumer-information-on-pinnacle-complete-acetabular-hip-system/</loc>
		<lastmod>2011-06-16T19:23:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 353: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/class-i-medical-device-recall-boston-scientific-innova-self-expanding-stent-system/</loc>
		<lastmod>2011-06-16T19:23:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 352: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/fda-drug-safety-communication-chantix-varenicline-may-increase-the-risk-of-certain-cardiovascular-adverse-events-in-patients-with-cardiovascular-disease/</loc>
		<lastmod>2011-06-16T19:23:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 350: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/summary-information-for-inform-her2-dual-ish-dna-probe-cocktail/</loc>
		<lastmod>2011-06-16T06:47:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 351: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/consumer-information-on-inform-her2-dual-ish-dna-probe-cocktail/</loc>
		<lastmod>2011-06-16T06:47:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 349: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/class-i-medical-device-recall-churchill-medical-vygon-skin-prep-wipes/</loc>
		<lastmod>2011-06-16T06:47:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 348: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/indomethacin-for-injection-recall-of-one-lot/</loc>
		<lastmod>2011-06-16T06:47:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 347: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/actos-pioglitazone-ongoing-safety-review/</loc>
		<lastmod>2011-06-16T06:47:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 346: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/16/fda-drug-safety-communication-update-to-ongoing-safety-review-of-actos-pioglitazone-and-increased-risk-of-bladder-cancer/</loc>
		<lastmod>2011-06-16T06:47:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 345: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/15/standard-operating-procedure-for-notice-to-industry-letters/</loc>
		<lastmod>2011-06-15T18:14:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 344: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/15/initial-results-of-510k-audit/</loc>
		<lastmod>2011-06-15T18:14:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 343: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/15/draft-guidance-for-industry-and-fda-staff-establishing-the-performance-characteristics-of-in-vitro-diagnostic-devices-for-the-detection-of-methicillin/</loc>
		<lastmod>2011-06-15T18:14:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 342: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/15/boston-scientific-icross-and-atlantis-sr-pro-2-coronary-imaging-catheters-recall-%e2%80%93-catheter-tip-can-break-inside-of-the-patient/</loc>
		<lastmod>2011-06-15T06:03:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 341: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/15/sunscreen/</loc>
		<lastmod>2011-06-15T06:03:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 340: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/15/questions-and-answers-fda-announces-new-requirements-for-over-the-counter-otc-sunscreen-products-marketed-in-the-u-s/</loc>
		<lastmod>2011-06-15T06:03:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 337: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/class-i-medical-device-recall-boston-scientific-icross-and-atlantis-sr-pro-2-coronary-imaging-catheters/</loc>
		<lastmod>2011-06-14T17:38:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 338: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/class-i-medical-device-recall-maquet-datascope-corp-intra-aortic-balloon-pumps/</loc>
		<lastmod>2011-06-14T17:38:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 339: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/class-i-medical-device-recall-terumo-coronary-ostia-cannula-10-12-14-fr/</loc>
		<lastmod>2011-06-14T17:38:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 336: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/flulaval/</loc>
		<lastmod>2011-06-14T17:38:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 335: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/maquet-datascope-corp-intra-aortic-balloon-pumps-recall-%e2%80%93-shuts-off-without-warning/</loc>
		<lastmod>2011-06-14T17:38:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 334: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/terumo-coronary-ostia-cannula-10-12-14-fr-recall-%e2%80%93-fragments-of-adhesive-and-plastic-in-the-cannula-tip-may-embolize/</loc>
		<lastmod>2011-06-14T17:38:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 332: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/drugs-to-be-discontinued/</loc>
		<lastmod>2011-06-14T04:22:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 333: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/risperidone-risperdal-and-ropinirole-requip-medication-errors/</loc>
		<lastmod>2011-06-14T04:22:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 331: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/14/fda-drug-safety-communication-medication-errors-resulting-from-confusion-between-risperidone-risperdal-and-ropinirole-requip/</loc>
		<lastmod>2011-06-14T04:22:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 330: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/13/victoza-liraglutide-rdna-origin-injection-rems-risk-of-thyroid-c/</loc>
		<lastmod>2011-06-13T16:09:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 329: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/09/510k-final-decisions/</loc>
		<lastmod>2011-06-09T23:21:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 326: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/09/questions-and-answers-5-alpha-reductase-inhibitors-5-aris-may-increase-the-risk-of-a-more-serious-form-of-prostate-cancer/</loc>
		<lastmod>2011-06-09T23:21:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 327: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/09/fda-drug-safety-communication-5-alpha-reductase-inhibitors-5-aris-may-increase-the-risk-of-a-more-serious-form-of-prostate-cancer/</loc>
		<lastmod>2011-06-09T23:21:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 328: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/09/5-alpha-reductase-inhibitors-5-aris-label-change/</loc>
		<lastmod>2011-06-09T23:21:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 325: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/09/zocor-simvastatin-label-change/</loc>
		<lastmod>2011-06-09T10:27:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 324: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/08/device-registration-and-listing-requirements-in-spanish/</loc>
		<lastmod>2011-06-08T22:03:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 323: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/08/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-for-zocor-simvastatin-to-reduce-the-risk-of-muscle-injury/</loc>
		<lastmod>2011-06-08T22:03:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 322: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/07/oridion-medical-and-philips-healthcare-microstream-co2-filterline-filterline-h-set-infantneonate-vitaline-h-set-infantneonate-recall/</loc>
		<lastmod>2011-06-07T18:10:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 321: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/07/via-xtreme-ultimate-sexual-enhancer-dietary-supplement-for-men-recall/</loc>
		<lastmod>2011-06-07T18:10:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 319: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/07/class-i-medical-device-recall-oridion-medical-and-philips-healthcare-microstream-co2-filterline-filterline-h-set-infantneonate-vitaline-h-set-infantneonate/</loc>
		<lastmod>2011-06-07T06:06:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 320: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/07/pma-final-decisions-for-april-2011/</loc>
		<lastmod>2011-06-07T06:06:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 318: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/03/consumer-information-on-xience-nano-everolimus-eluting-coronary-stent-system/</loc>
		<lastmod>2011-06-04T03:14:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 317: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/03/guidance-for-industry-and-food-and-drug-administration-staff-assemblers-guide-to-diagnostic-x/</loc>
		<lastmod>2011-06-04T03:14:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 316: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/03/aidapak-services-repackaged-pharmaceuticals-recall/</loc>
		<lastmod>2011-06-04T03:14:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 315: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/03/summary-information-for-xience-nano-everolimus-eluting-coronary-stent-system/</loc>
		<lastmod>2011-06-03T14:24:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 313: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/03/consumer-information-on-exoseal-vascular-closure-device/</loc>
		<lastmod>2011-06-03T14:24:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 314: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/03/summary-information-for-exoseal-vascular-closure-device/</loc>
		<lastmod>2011-06-03T14:24:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 312: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/03/flumist/</loc>
		<lastmod>2011-06-03T14:24:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 311: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/02/fda-safety-communication-breast-cancer-screening/</loc>
		<lastmod>2011-06-03T02:22:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 310: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/02/angiotensin-receptor-blockers-arbs-drug-safety-communication/</loc>
		<lastmod>2011-06-03T02:22:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 309: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/02/thermographic-imaging-systems-for-breast-cancer-screening-fda-safety-communication/</loc>
		<lastmod>2011-06-03T02:22:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 308: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/02/fda-drug-safety-communication-no-increase-in-risk-of-cancer-with-certain-blood-pressure-drugs-angiotensin-receptor-blockers-arbs/</loc>
		<lastmod>2011-06-03T02:22:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 307: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/02/letter-to-foreign-and-domestic-medical-device-and-component-establishments-that-may-be-affected-by-the-march-2011-japan-earthquake-and-tsunami/</loc>
		<lastmod>2011-06-02T12:30:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 306: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/01/information-on-drugs-of-abuse-tests-updated/</loc>
		<lastmod>2011-06-01T23:59:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 305: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/01/draft-guidance-for-industry-and-fda-staff-4/</loc>
		<lastmod>2011-06-01T23:59:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 304: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/01/cdrh-learn-new-course-available/</loc>
		<lastmod>2011-06-01T23:59:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 301: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/31/questions-and-answers-%e2%80%93-ongoing-safety-review-of-birth-control-pills-containing-drospirenone-and-a-possible-increased-risk-of-blood-clots/</loc>
		<lastmod>2011-05-31T22:43:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 302: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/31/fda-drug-safety-communication-safety-review-of-possible-increased-risk-of-blood-clots-with-birth-control-pills-containing-drospirenone/</loc>
		<lastmod>2011-05-31T22:43:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 303: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/31/birth-control-pills-containing-drospirenone-possible-increased-risk-of-blood-clots/</loc>
		<lastmod>2011-05-31T22:43:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 300: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/26/generic-drugs-information-for-industry/</loc>
		<lastmod>2011-05-26T16:44:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 299: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/26/cder-key-officials-list/</loc>
		<lastmod>2011-05-26T16:44:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 298: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/26/fda-statement-on-the-aim-high-trial/</loc>
		<lastmod>2011-05-26T16:44:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 297: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/24/premarket-approval-pma-summary-review-memos-for-180-day-design-changes-p010030s023-and-p890003s209/</loc>
		<lastmod>2011-05-24T14:18:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 295: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/23/class-i-medical-device-recall-beckman-coulter-inc-synchron-lx-clinical-systems-ion-selective-electrolyte-ise-flow-cell/</loc>
		<lastmod>2011-05-24T00:53:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 296: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/23/fda-medical-device-2010-quality-system-data/</loc>
		<lastmod>2011-05-24T00:53:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 294: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/23/pentrexyl-forte-natural-recall/</loc>
		<lastmod>2011-05-24T00:53:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 293: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/23/beckman-coulter-inc-synchron-lx-clinical-systems-ion-selective-electrolyte-ise-flow-cell-class-i-recall/</loc>
		<lastmod>2011-05-24T00:53:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 292: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/20/consumer-information-on-abbott-realtime-hcv/</loc>
		<lastmod>2011-05-21T02:23:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 291: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/20/summary-information-for-abbott-realtime-hcv/</loc>
		<lastmod>2011-05-21T02:23:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 290: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/20/simplythick-public-health-notification-risk-of-life/</loc>
		<lastmod>2011-05-21T02:23:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 288: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/19/summary-information-for-vitros-immunodiagnostic-products-hbeag-reagent-pack-calibrator-and-controls/</loc>
		<lastmod>2011-05-20T01:29:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 289: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/19/consumer-information-on-vitros-immunodiagnostic-products-hbeag-reagent-pack-calibrator-and-controls/</loc>
		<lastmod>2011-05-20T01:29:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 287: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/19/public-meeting-ultra-high-throughput-sequencing-for-clinical-diagnostic-applications/</loc>
		<lastmod>2011-05-20T01:29:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 286: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/19/chantix-quarterwatch-article/</loc>
		<lastmod>2011-05-19T18:56:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 285: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/19/fda-drug-safety-communication-updated-risk-evaluation-and-mitigation-strategy-rems-to-restrict-access-to-rosiglitazone-containing-medicines-including-avandia-avandamet-and-avandaryl/</loc>
		<lastmod>2011-05-19T06:27:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 282: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/18/cdrh-learn-new-courses-available-in-spanish-and-chinese/</loc>
		<lastmod>2011-05-19T00:26:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 283: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/18/cdrh-osel-recruitment-for-orise-post-doctoral-researcher-in-polymer-chemistry/</loc>
		<lastmod>2011-05-19T00:26:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 284: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/18/draft-guidance-for-industry-and-food-and-drug-administration-staff-3/</loc>
		<lastmod>2011-05-19T00:26:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 281: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/18/avandia-rosiglitazone-rems/</loc>
		<lastmod>2011-05-19T00:26:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 280: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/18/fda-significantly-restricts-access-to-the-diabetes-drug-avandia/</loc>
		<lastmod>2011-05-18T18:21:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 279: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/16/extenze-tablets-recall/</loc>
		<lastmod>2011-05-16T21:06:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 277: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/14/consumer-information-on-rx-acculink-carotid-stent-system/</loc>
		<lastmod>2011-05-14T06:47:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 278: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/14/summary-information-for-rx-acculink-carotid-stent-system/</loc>
		<lastmod>2011-05-14T06:47:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 276: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/13/letter-to-precision-quality-dna-concerning-direct-to-consumer-advertising/</loc>
		<lastmod>2011-05-13T18:02:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 275: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/13/letter-to-lumigenix-inc-concerning-direct-to-consumer-advertising/</loc>
		<lastmod>2011-05-13T18:02:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 274: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/13/letter-to-american-international-biotechnology-services-concerning-direct-to-consumer-advertising/</loc>
		<lastmod>2011-05-13T18:02:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 273: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/13/postmarketing-drug-safety-evaluations/</loc>
		<lastmod>2011-05-13T11:59:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 272: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/13/minutes-from-stakeholder-meeting-on-mdufa-iii-reauthorization-april-27-2011/</loc>
		<lastmod>2011-05-13T05:55:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 270: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/13/summary-information-for-ion-paclitaxel-eluting-coronary-stent-system/</loc>
		<lastmod>2011-05-13T05:55:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 271: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/13/consumer-information-on-ion-paclitaxel-eluting-coronary-stent-system/</loc>
		<lastmod>2011-05-13T05:55:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 269: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/12/agenda-and-materials-from-may-4-2011-fda-mdufma-mdufa-performance-report-pdf/</loc>
		<lastmod>2011-05-12T17:44:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 268: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/12/consumer-information-on-acrysof-toric-intraocular-lens-iol/</loc>
		<lastmod>2011-05-12T17:44:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 267: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/12/summary-information-for-acrysof-toric-intraocular-lens-iol/</loc>
		<lastmod>2011-05-12T17:44:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 266: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/12/fluzone-fluzone-high-dose-and-fluzone-intradermal/</loc>
		<lastmod>2011-05-12T17:44:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 265: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/11/class-i-medical-device-recall-defibtech-llc-lifeline-and-reviver-aeds-software-defect-may-cancel-shock/</loc>
		<lastmod>2011-05-11T17:24:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 264: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/11/premarket-approval-pma-summary-review-memos-for-180-day-design-changes-selectsecure-model-3830-lead/</loc>
		<lastmod>2011-05-11T17:24:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 263: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/11/draft-guidance-for-industry-and-food-and-drug-administration-staff-2/</loc>
		<lastmod>2011-05-11T17:24:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 262: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/11/defibtech-lifeline-and-reviver-automated-external-defibrillators-aeds-recall/</loc>
		<lastmod>2011-05-11T17:24:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 261: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/11/slim-xtreme-herbal-slimming-capsule-undeclared-drug-ingredient/</loc>
		<lastmod>2011-05-11T17:24:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 260: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/11/consumer-information-on-scandinavian-total-ankle-replacement-system-star-ankle/</loc>
		<lastmod>2011-05-11T04:23:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 259: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/11/summary-information-for-scandinavian-total-ankle-replacement-system-star-ankle/</loc>
		<lastmod>2011-05-11T04:23:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 258: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/10/class-i-medical-device-recall-defibtech-llc-lifeline-and-reviver-aeds/</loc>
		<lastmod>2011-05-10T16:01:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 257: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/10/multi-mex-distributor-inc-dietary-supplements-recall/</loc>
		<lastmod>2011-05-10T16:01:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 256: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/07/consumer-information-on-st-jude-medical-trifecta-valve/</loc>
		<lastmod>2011-05-07T11:31:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 255: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/07/fda-drug-safety-communication-connection-problems-involving-certain-needleless-pre-filled-glass-syringes-containing-adenosine-and-amiodarone/</loc>
		<lastmod>2011-05-07T05:12:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 252: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/06/consumer-information-on-cobas-hpv-test/</loc>
		<lastmod>2011-05-06T22:21:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 253: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/06/consumer-information-on-cpax-aneurysm-treatment-system/</loc>
		<lastmod>2011-05-06T22:21:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 254: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/06/consumer-information-on-novottf-100a-system/</loc>
		<lastmod>2011-05-06T22:21:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 251: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/06/weck-hem-o-lok-ligating-clips-contraindicated-for-ligation-of-renal-artery-during-laparoscopic-living-donor-nephrectomy/</loc>
		<lastmod>2011-05-06T22:21:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 250: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/05/fda-and-hrsa-joint-safety-communication-weck-hem-o-lok-ligating-clips-contraindicated-for-ligation-of-renal-artery-during-laparoscopic-living-donor-nephrectomy/</loc>
		<lastmod>2011-05-05T20:36:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 249: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/05/april-2011-510k-clearances/</loc>
		<lastmod>2011-05-05T20:36:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 248: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/04/questions-and-answers-on-guidance-for-industry-dosage-delivery-devices-for-orally-ingested-otc-liquid-drug-products/</loc>
		<lastmod>2011-05-05T01:04:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 247: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/04/boston-scientific-devices-stolen-%e2%80%93-risk-of-infection/</loc>
		<lastmod>2011-05-04T18:33:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 246: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/04/mqsa-national-statistics/</loc>
		<lastmod>2011-05-04T06:11:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 245: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/03/class-i-medical-device-recall-biomrieux-inc-vitek-2-gram-negative-susceptibility-cards-containing-piperacillintazobactam-tzp2-expanded-recall/</loc>
		<lastmod>2011-05-03T17:24:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 244: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/03/coumadin-warfarin-sodium-crystalline-5-mg-tablets-recall/</loc>
		<lastmod>2011-05-03T17:24:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 243: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/02/regenerect-recall/</loc>
		<lastmod>2011-05-03T03:36:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 242: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/30/consumer-information-on-gel-one-2/</loc>
		<lastmod>2011-04-30T13:05:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 241: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/30/public-workshop-reprocessing-of-reusable-medical-devices-june-8/</loc>
		<lastmod>2011-04-30T13:05:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 240: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/30/pma-final-decisions-for-march-2011/</loc>
		<lastmod>2011-04-30T13:05:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 239: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/29/information-on-reprocessing-of-reusable-medical-devices/</loc>
		<lastmod>2011-04-30T00:32:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 238: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/29/evaluation-of-automatic-class-iii-designation-de-novo-decision-summaries-added-k101699/</loc>
		<lastmod>2011-04-30T00:32:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 237: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/29/draft-guidance-for-industry-and-fda-staff-3/</loc>
		<lastmod>2011-04-30T00:32:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 236: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/29/natural-disaster-response/</loc>
		<lastmod>2011-04-29T05:56:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 235: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/28/public-workshop-2/</loc>
		<lastmod>2011-04-28T23:47:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 233: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/26/premarket-approval-pma-summary-review-memos-for-180-day-design-changes-new-memos-available/</loc>
		<lastmod>2011-04-26T12:03:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 234: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/26/premarket-approval-pma-summary-review-memos-for-180-day-design-changes-new-memos-available/</loc>
		<lastmod>2011-04-26T12:03:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 232: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/25/consumer-information-on-mel-80-excimer-laser-system/</loc>
		<lastmod>2011-04-25T22:01:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 231: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/25/summary-information-for-mel-80-excimer-laser-system/</loc>
		<lastmod>2011-04-25T22:01:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 230: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/25/guidance-for-industry-and-fda-staff-5/</loc>
		<lastmod>2011-04-25T22:01:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 229: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/22/fda-drug-safety-communication-safety-update-on-progressive-multifocal-leukoencephalopathy-pml-associated-with-tysabri-natalizumab/</loc>
		<lastmod>2011-04-23T03:03:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 228: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/22/tysabri-natalizumab-update-of-healthcare-professional-information/</loc>
		<lastmod>2011-04-22T21:03:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 227: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/21/summary-information-for-valiant-thoracic-stent-graft-with-the-captiva-delivery-system/</loc>
		<lastmod>2011-04-21T07:32:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 226: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/fda-drug-info-rounds/</loc>
		<lastmod>2011-04-21T01:26:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 225: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/potential-signals-of-serious-risksnew-safety-information-identified-from-the-adverse-event-reporting-system-aers/</loc>
		<lastmod>2011-04-21T01:26:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 224: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/consumer-information-on-valiant-thoracic-stent-graft-with-the-captiva-delivery-system/</loc>
		<lastmod>2011-04-20T19:18:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 222: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/summary-information-for-pipeline-embolization-device/</loc>
		<lastmod>2011-04-20T19:18:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 223: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/consumer-information-on-pipeline-embolization-device/</loc>
		<lastmod>2011-04-20T19:18:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 221: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/glassia/</loc>
		<lastmod>2011-04-20T19:18:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 220: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/communicating-drug-safety-messages/</loc>
		<lastmod>2011-04-20T19:18:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 219: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/20/medical-device-data-systems/</loc>
		<lastmod>2011-04-20T06:06:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 218: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/19/steris-system-1-processor-6-month-extension-for-healthcare-facilities-to-transition-to-legally-marketed-alternatives/</loc>
		<lastmod>2011-04-19T17:55:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 217: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/15/fda-drug-safety-communication-drug-labels-now-contain-updated-recommendations-on-the-appropriate-use-of-long-acting-inhaled-asthma-medications-called-long-acting-beta-agonists-labas/</loc>
		<lastmod>2011-04-16T02:57:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 216: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/15/fda-drug-safety-communication-fda-requires-post-market-safety-trials-for-long-acting-beta-agonists-labas/</loc>
		<lastmod>2011-04-16T02:57:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 215: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/15/topamax-topiramate-recall/</loc>
		<lastmod>2011-04-15T20:55:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 214: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/15/lansoprazole-delayed-release-orally-disintegrating-tablets-by-teva-pharmaceuticals-letter-to-healthcare-professionals/</loc>
		<lastmod>2011-04-15T20:55:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 213: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/15/long-acting-beta-agonists-labas-new-safe-use-requirements/</loc>
		<lastmod>2011-04-15T20:55:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 212: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/fda-drug-safety-communication-safety-review-update-of-benicar-olmesartan-and-cardiovascular-events/</loc>
		<lastmod>2011-04-15T02:15:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 211: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/fda-drug-safety-communication-safety-review-update-on-reports-of-hepatosplenic-t-cell-lymphoma-in-adolescents-and-young-adults-receiving-tumor-necrosis-factor-tnf-blockers-azathioprine-andor-merc/</loc>
		<lastmod>2011-04-15T02:15:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 210: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/guidance-for-industry-and-fda-staff-4/</loc>
		<lastmod>2011-04-14T19:32:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 209: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/guidance-for-industry-and-fda-staff-30-day-notices-135-day-premarket-approval-pma-supplements-and-75/</loc>
		<lastmod>2011-04-14T19:32:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 208: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/clinical-investigator-status-biologics/</loc>
		<lastmod>2011-04-14T19:32:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 207: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/benicar-olmesartan-ongoing-safety-review/</loc>
		<lastmod>2011-04-14T19:32:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 206: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/tumor-necrosis-factor-tnf-blockers-azathioprine-andor-mercaptopurine-update-on-reports-of-hepatosplenic-t-cell-lymphoma-in-adolescents-and-young-adults/</loc>
		<lastmod>2011-04-14T19:32:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 205: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/class-i-medical-device-recall-penumbra-inc-penumbra-coil-400/</loc>
		<lastmod>2011-04-14T06:32:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 204: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/class-i-medical-device-recall-icad-formerly-xoft-inc-axxent-flexishield-mini-model-f5300/</loc>
		<lastmod>2011-04-14T06:32:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 203: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/axxent-flexishield-mini-by-icad-formerly-xoft-inc-recall-product-may-shed-particles-of-tungsten/</loc>
		<lastmod>2011-04-14T06:32:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 202: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/14/penumbra-coil-400-by-penumbra-inc-class-1-recall/</loc>
		<lastmod>2011-04-14T06:32:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 201: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/13/april-8-2011-approval-letter-rotateq/</loc>
		<lastmod>2011-04-13T17:52:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 200: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/13/april-5-2011-approval-letter/</loc>
		<lastmod>2011-04-13T05:05:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 199: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/12/pediatric-exclusivity-statistics/</loc>
		<lastmod>2011-04-12T23:04:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 198: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/12/written-requests-issued/</loc>
		<lastmod>2011-04-12T23:04:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 197: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/09/revlimid-lenalidomide-ongoing-safety-review/</loc>
		<lastmod>2011-04-09T08:30:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 196: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/08/fda-drug-safety-communication-ongoing-safety-review-of-revlimid-lenalidomide-and-possible-increased-risk-of-developing-new-malignancies/</loc>
		<lastmod>2011-04-09T02:16:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 195: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/07/fda-drug-safety-communication-reports-of-a-rare-but-serious-and-potentially-fatal-adverse-effect-with-the-use-of-over-the-counter-otc-benzocaine-gels-and-liquids-applied-to-the-gums-or-mouth/</loc>
		<lastmod>2011-04-07T23:32:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 194: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/07/fda-drug-safety-communication-fda-continues-to-receive-reports-of-a-rare-but-serious-and-potentially-fatal-adverse-effect-with-the-use-of-benzocaine-sprays-for-medical-procedures/</loc>
		<lastmod>2011-04-07T23:32:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 193: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/07/benzocaine-topical-products-sprays-gels-and-liquids/</loc>
		<lastmod>2011-04-07T17:15:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 192: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/06/pma-final-decisions-for-february-2011/</loc>
		<lastmod>2011-04-06T16:37:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 191: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/06/fda-workshop-seizure-detection-cognitive-function-and-tbiconcussion-devices-issues-in-their-evaluation-june-2/</loc>
		<lastmod>2011-04-06T16:37:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 190: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/06/yervoy-ipilimumab-risk-evaluation-and-mitigation-strategy-rems-severe-immune/</loc>
		<lastmod>2011-04-06T16:37:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 189: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/05/pma-final-decisions-for-january-2011/</loc>
		<lastmod>2011-04-06T03:48:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 188: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/05/federal-register-risk-communication-advisory-committee-notice-of-meeting/</loc>
		<lastmod>2011-04-05T15:27:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 187: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/05/best-enhancer-recall-%e2%80%93-undeclared-drug-ingredient/</loc>
		<lastmod>2011-04-05T15:27:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 186: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/04/guidance-for-industry-and-fda-staff-3/</loc>
		<lastmod>2011-04-05T03:05:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 185: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/04/summary-information-for-selenia-dimensions-3d-system/</loc>
		<lastmod>2011-04-04T13:39:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 184: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/04/consumer-information-on-selenia-dimensions-3d-system/</loc>
		<lastmod>2011-04-04T13:39:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 183: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/04/summary-information-for-oraquick-hcv-rapid-antibody-test/</loc>
		<lastmod>2011-04-04T13:39:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 182: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/consumer-information-on-oraquick-hcv-rapid-antibody-test/</loc>
		<lastmod>2011-04-04T01:25:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 181: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/fda-safety-notification-mammography-problems-at-huntington-radiology-in-huntington-park-california/</loc>
		<lastmod>2011-04-04T01:25:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 180: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/fda-esubmitter-radiation-safety-report-video-tutorial-and-updated-user-guide/</loc>
		<lastmod>2011-04-04T01:25:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 179: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/cook-inc-single-double-triple-and-five-lumen-central-venous-catheter-trays-and-single-and-double-lumen-picc-peripheral-inserted-central-venous-catheter-trays-class-i-recall/</loc>
		<lastmod>2011-04-04T01:25:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 178: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/town-hall-discussion-with-the-director-of-cdrh-and-other-senior-center-management-may-5-2011-revised-phone-number/</loc>
		<lastmod>2011-04-03T11:32:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 177: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/510k-implementation-discussion-of-an-on-line-repository-of-medical-device-labeling-and-of-making-device-photographs-available-in-a-public-database-without-disclosing-proprietary-information-april/</loc>
		<lastmod>2011-04-03T11:32:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 176: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/federal-register-guidance-for-industry-and-food-and-drug-administration-staff-class-ii-special-controls-guidance-document-ovarian-adnexal-mass-assessment-score-test-system-availability/</loc>
		<lastmod>2011-04-03T11:32:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 175: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/davol-xenmatrix-surgical-graft-class-i-recall/</loc>
		<lastmod>2011-04-03T11:31:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 174: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/topamax-topiramate-label-change/</loc>
		<lastmod>2011-04-03T11:31:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 173: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/03/kaletra-lopinavirritonavir-label-change/</loc>
		<lastmod>2011-04-03T11:31:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 172: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/class-i-medical-device-recall-gen-probe-inc-accuprobe-group-b-streptococcus-culture-identification-test-accuprobe-mycobacterium-tuberculosis-complex-culture-identification-test-and-accuprobe-myco/</loc>
		<lastmod>2011-04-02T22:03:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 171: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/consumer-information-on-lap-band-adjustable-gastric-banding-system/</loc>
		<lastmod>2011-04-02T22:03:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 170: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/guidance-for-industry-and-fda-staff-2/</loc>
		<lastmod>2011-04-02T22:03:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 169: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/black-ant-undeclared-drug-ingredient/</loc>
		<lastmod>2011-04-02T22:03:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 168: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/gen-probe-inc-accuprobe-group-b-streptococcus-culture-identification-test-accuprobe-mycobacterium-tuberculosis-complex-culture-identification-test-and-accuprobe-mycobacterium-avium-complex-culture/</loc>
		<lastmod>2011-04-02T22:03:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 167: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/american-regent-injectable-products-recall/</loc>
		<lastmod>2011-04-02T22:03:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 165: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/additionsdeletions-for-prescription-and-otc-drug-product-lists/</loc>
		<lastmod>2011-04-02T15:39:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 166: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/orange-book-zip-file/</loc>
		<lastmod>2011-04-02T15:39:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 164: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/letter-to-industry-about-import-entry-review-process/</loc>
		<lastmod>2011-04-02T09:11:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 163: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/consumer-information-on-elana-surgical-kithud/</loc>
		<lastmod>2011-04-02T09:11:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 162: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/summary-information-for-elana-surgical-kithud/</loc>
		<lastmod>2011-04-02T09:11:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 161: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/h-p-industries-povidone-iodine-prep-pads-recall/</loc>
		<lastmod>2011-04-02T09:11:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 160: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/u-prosta-undeclared-drug-ingredient/</loc>
		<lastmod>2011-04-02T09:11:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 159: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/02/citalopram-and-finasteride-by-greenstone-recall/</loc>
		<lastmod>2011-04-02T09:11:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 157: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/warning-letters-2011/</loc>
		<lastmod>2011-04-02T03:07:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 158: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/fda-drug-safety-communication-possible-increased-risk-of-fractures-of-the-hip-wrist-and-spine-with-the-use-of-proton-pump-inhibitors/</loc>
		<lastmod>2011-04-02T03:07:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 156: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/clinical-investigator-inspection-list-cliil/</loc>
		<lastmod>2011-04-02T03:07:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 155: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/class-i-medical-device-recall-roche-insulin-delivery-systems-accu-chek-flexlink-plus-infusion-sets/</loc>
		<lastmod>2011-04-01T21:00:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 154: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/class-i-medical-device-recall-millar-instruments-inc-mikro-tip-angiographic-catheter-model-spc-454d-and-spc-454f/</loc>
		<lastmod>2011-04-01T21:00:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 153: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/cdrh-plan-of-action-for-510k-and-science-added-cdrh-center-science-council-draft-charter-and-faqs/</loc>
		<lastmod>2011-04-01T21:00:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 152: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/complete-list-of-currently-approved-nda-and-anda-application-submissions/</loc>
		<lastmod>2011-04-01T21:00:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 151: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/complete-list-of-currently-approved-premarket-approvals-pmas/</loc>
		<lastmod>2011-04-01T21:00:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 150: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/february-24-2011-approval-letter/</loc>
		<lastmod>2011-04-01T21:00:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 149: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/irinotecan-hydrochloride-injection-recall/</loc>
		<lastmod>2011-04-01T21:00:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 148: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/mikro-tip-angiographic-catheter-model-spc-454d-and-spc-454f-by-millar-instruments-inc-class-1-recall/</loc>
		<lastmod>2011-04-01T21:00:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 147: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/heartstring-ii-proximal-seal-system-hs-1045-by-maquet-cardiovascular-llc-recall/</loc>
		<lastmod>2011-04-01T21:00:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 146: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/fda-drug-safety-communication-special-storage-and-handling-requirements-must-be-followed-for-pradaxa-dabigatran-etexilate-mesylate-capsules/</loc>
		<lastmod>2011-04-01T14:41:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 145: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/pediatric-exclusivity-granted/</loc>
		<lastmod>2011-04-01T14:41:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 144: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/current-drug-shortages/</loc>
		<lastmod>2011-04-01T14:41:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 141: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/class-i-medical-device-recall-maquet-cardiovascular-llc-heartstring-ii-proximal-seal-system-hs-1045/</loc>
		<lastmod>2011-04-01T08:07:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 142: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/consumer-information-on-medtronic-interstim-therapy-system/</loc>
		<lastmod>2011-04-01T08:07:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 143: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/summary-information-for-medtronic-interstim-therapy-system/</loc>
		<lastmod>2011-04-01T08:07:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 140: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/human-cell-tissues-and-cellular-and-tissue-based-products-hctp-list-of-registered-establishments/</loc>
		<lastmod>2011-04-01T08:07:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 139: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/adenovirus-type-4-and-type-7-vaccine-live-oral/</loc>
		<lastmod>2011-04-01T08:07:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 138: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/jobs-at-the-center-for-biologics-evaluation-and-research-cber/</loc>
		<lastmod>2011-04-01T08:07:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 137: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/celerite-slimming-tea-recall/</loc>
		<lastmod>2011-04-01T08:07:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 136: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/soladek-vitamin-solution-unapproved-product-may-contain-dangerously-high-levels-of-vitamins-a-and-d/</loc>
		<lastmod>2011-04-01T08:07:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 135: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/roche-accu-chek-flexlink-plus-infusion-set-class-i-recall-potential-for-under/</loc>
		<lastmod>2011-04-01T08:07:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 134: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/single-ingredient-oral-colchicine-video/</loc>
		<lastmod>2011-04-01T08:07:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 133: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/01/long-acting-beta-agonists-labas-video/</loc>
		<lastmod>2011-04-01T08:07:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 132: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/newly-added-guidance-documents/</loc>
		<lastmod>2011-04-01T01:44:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 131: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/truthful-prescription-drug-advertising-and-promotion-bad-ad-program/</loc>
		<lastmod>2011-04-01T01:44:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 130: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/drugsfda-data-files/</loc>
		<lastmod>2011-04-01T01:44:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 129: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/lasik-quality-of-life-project/</loc>
		<lastmod>2011-03-31T19:35:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 128: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/summary-information-for-gel-one/</loc>
		<lastmod>2011-03-31T19:35:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 127: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/consumer-information-on-gel-one/</loc>
		<lastmod>2011-03-31T19:35:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 126: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/march-24-2011-approval-letter/</loc>
		<lastmod>2011-03-31T19:35:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 125: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/influenza-virus-vaccine-for-the-2010-2011-season/</loc>
		<lastmod>2011-03-31T19:35:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 124: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/december-1-2010-approval-letter/</loc>
		<lastmod>2011-03-31T19:35:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 123: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/x-hero-and-male-enhancer-recall/</loc>
		<lastmod>2011-03-31T19:35:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 122: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/pradaxa-dabigatran-etexilate-mesylate-capsules-special-storage-and-handling-requirements/</loc>
		<lastmod>2011-03-31T19:35:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 121: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/meds-iv-pharmacy-iv-compounded-products-recall-outbreak-of-serratia-marcescens-bacteremia-in-alabama-hospitals/</loc>
		<lastmod>2011-03-31T19:35:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 120: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/proton-pump-inhibitors-ppis-video/</loc>
		<lastmod>2011-03-31T19:35:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 118: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/drug-shortages-video/</loc>
		<lastmod>2011-03-31T19:35:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 119: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/31/evamist-video/</loc>
		<lastmod>2011-03-31T19:35:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 115: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/20/class-i-medical-device-recall-fresenius-medical-care-north-america-combiset-true-flow-series-hemodialysis-blood-tubing-set-with-priming-set-and-transducer-protectors-for-use-with-the-blood-volume-mo/</loc>
		<lastmod>2011-01-21T01:41:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 114: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/20/sopp-8406-managing-pdufa-user-fee-payments-and-billing-activities/</loc>
		<lastmod>2011-01-21T01:41:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 113: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/19/january-13-2011-approval-letter/</loc>
		<lastmod>2011-01-20T00:11:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 112: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/14/cdrh-ombudsman-annual-report/</loc>
		<lastmod>2011-01-14T22:30:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 111: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/14/consumer-information-on-arctic-front-cardiac-cryoablation-catheter/</loc>
		<lastmod>2011-01-14T22:30:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 110: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/13/acetaminophen-information/</loc>
		<lastmod>2011-01-13T21:05:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 109: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/13/acetaminophen-prescription-products-limited-to-325-mg-per-dosage-unit-drug-safety-communication/</loc>
		<lastmod>2011-01-13T21:05:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 108: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/13/fda-drug-safety-communication-update-to-ongoing-safety-review-of-lantus-insulin-glargine-and-possible-risk-of-cancer/</loc>
		<lastmod>2011-01-13T08:31:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 107: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/12/safe-use-initiative-fda-sponsored-stakeholder-meeting-on-surgical-fire-prevention/</loc>
		<lastmod>2011-01-12T06:49:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 106: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/12/town-hall-discussion-with-the-director-of-cdrh-and-other-senior-center-management-march-10-2011/</loc>
		<lastmod>2011-01-12T06:49:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 105: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/07/triad-alcohol-prep-pads-alcohol-swabs-and-alcohol-swabsticks-recall-due-to-potential-microbial-contamination/</loc>
		<lastmod>2011-01-07T09:01:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 104: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/05/class-i-medical-device-recall-angioscore-inc-angiosculpt-percutaneous-transluminal-angioplasty-pta-scoring-balloon-catheterotw-0-018-platform-multiple-sizes/</loc>
		<lastmod>2011-01-05T19:43:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 103: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/04/albuterol-sulfate-inhalation-solution-0-083-3-ml-unit-dose-vials-recall/</loc>
		<lastmod>2011-01-04T05:15:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 102: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/29/class-i-medical-device-recall-arrow-ultra-8-intra-aortic-balloon-catheters-iabs-8-fr-30cc-and-40cc-universal-and-arrow-intra-aortic-balloon-iab-catheter-with-a-fiber-optic-sensor-and-measurement/</loc>
		<lastmod>2010-12-30T02:08:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 101: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/29/sodium-bicarbonate-injection-usp-7-5-and-8-4-50-ml-single-dose-vials/</loc>
		<lastmod>2010-12-30T02:08:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 100: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/28/class-i-medical-device-recall-ev3-nanocross-014-otw-pta-dilatation-catheter/</loc>
		<lastmod>2010-12-29T00:53:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 99: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/23/fda-drug-safety-communication-ongoing-safety-review-of-recombinant-human-growth-hormone-somatropin-and-possible-increased-risk-of-death/</loc>
		<lastmod>2010-12-23T04:09:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 98: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/23/questions-and-answers-about-the-abbott-glucose-test-strip-recall/</loc>
		<lastmod>2010-12-23T04:09:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 97: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/23/recombinant-human-growth-hormone-somatropin-ongoing-safety-review/</loc>
		<lastmod>2010-12-23T04:08:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 96: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/21/post-approval-study-database-updated-with-new-data-fields-describing-the-study-protocol/</loc>
		<lastmod>2010-12-22T03:30:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 95: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/21/class-i-medical-device-recall-fresenius-kabi-llc-red-blood-cell-rbc-exchange-sets-used-on-as104-blood-cell-separation-devices/</loc>
		<lastmod>2010-12-22T03:30:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 94: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/17/fda-drug-safety-communication-abnormal-heart-rhythms-associated-with-use-of-anzemet-dolasetron-mesylate/</loc>
		<lastmod>2010-12-17T18:26:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 93: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/16/fda-safety-notification-risk-of-eye-and-skin-injuries-from-high-powered-hand-held-lasers-used-for-pointing-or-entertainment/</loc>
		<lastmod>2010-12-16T16:31:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 92: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/14/fda-drug-safety-communication-death-resulting-from-overdose-after-accidental-ingestion-of-tessalon-benzonatate-by-children-under-10-years-of-age/</loc>
		<lastmod>2010-12-15T01:07:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 91: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/08/cord-blood-banking-%e2%80%93-information-for-consumers/</loc>
		<lastmod>2010-12-08T20:45:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 90: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/07/cord-blood-banking-%e2%80%93-information-for-consumers-december-7-2010/</loc>
		<lastmod>2010-12-07T19:34:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 89: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/02/remarks-massmedic-fda-update-conference-december-1-2010/</loc>
		<lastmod>2010-12-03T03:51:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 88: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/30/class-i-medical-device-recall-baxter-colleague-single-and-triple-channel-volumetric-infusion-pumps/</loc>
		<lastmod>2010-11-30T21:21:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 87: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/30/class-i-medical-device-recall-b-braun-addease-binary-connector/</loc>
		<lastmod>2010-11-30T21:21:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 86: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/30/class-i-medical-device-recall-walkmed-inc-triton-pole-mount-infusion-pump/</loc>
		<lastmod>2010-11-30T08:44:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 85: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/29/use-of-fingerstick-devices-on-more-than-one-person-poses-risk-for-transmitting-bloodborne-pathogens-initial-communication-update-11292010/</loc>
		<lastmod>2010-11-29T20:38:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 84: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/29/guidance-for-industry-and-food-and-drug-administration-staff/</loc>
		<lastmod>2010-11-29T20:38:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 83: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/29/draft-guidance-for-industry-and-food-and-drug-administration-staff/</loc>
		<lastmod>2010-11-29T20:38:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 82: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/23/class-i-medical-device-recall-micromedics-inc-surgical-sealant-dispensers-micromedics-nasal-septal-buttons-and-otological-ventilation-tubes-sealed-in-pouches/</loc>
		<lastmod>2010-11-24T01:06:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 81: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/23/consumer-information-on-boston-scientific-cardiac-resynchronization-therapy-defibrillators/</loc>
		<lastmod>2010-11-24T01:06:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 80: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/19/fda-drug-safety-communication-fda-recommends-against-the-continued-use-of-propoxyphene/</loc>
		<lastmod>2010-11-19T16:51:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 79: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/19/needleless-pre-filled-glass-syringes-stakeholder-advisory/</loc>
		<lastmod>2010-11-19T04:33:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 78: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/17/safe-use-initiative-expert-roundtable-on-pain-management-in-older-adults/</loc>
		<lastmod>2010-11-18T03:59:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 77: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/16/november-4-2010-approval-letter/</loc>
		<lastmod>2010-11-16T05:59:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 76: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/15/letter-to-manufacturers-of-external-defibrillators-about-developing-safer-products/</loc>
		<lastmod>2010-11-15T16:50:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 75: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/15/fda-public-workshop-on-external-defibrillators-december-15-16-2010/</loc>
		<lastmod>2010-11-15T16:50:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 74: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/14/sigma-spectrum-infusion-pump-model-35700-class-1-recall-risk-of-over-infusion/</loc>
		<lastmod>2010-11-14T15:33:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 73: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/12/class-i-medical-device-recall-sigma-spectrum-infusion-pump-model-35700/</loc>
		<lastmod>2010-11-13T01:59:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 72: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/10/class-i-medical-device-recall-biomrieux-inc-vitek-2-gram-negative-susceptibility-cards-containing-piperacillintazobactam-tzp/</loc>
		<lastmod>2010-11-10T21:34:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 71: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/09/safety-investigation-of-ct-brain-perfusion-scans-update-1192010/</loc>
		<lastmod>2010-11-09T20:22:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 70: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/09/federal-register-draft-guidance-emergency-use-authorization-of-medical-products-66104-201027160/</loc>
		<lastmod>2010-11-09T07:13:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 69: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/05/information-on-products-for-security-screening-of-people/</loc>
		<lastmod>2010-11-05T20:03:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 68: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/05/fda-patient-safety-news-for-november-2010/</loc>
		<lastmod>2010-11-05T20:03:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 67: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/05/information-on-security-screening-of-people/</loc>
		<lastmod>2010-11-05T06:17:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 66: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/05/hospira-symbiq-one-channel-and-two-channel-infusers-class-i-recall-2/</loc>
		<lastmod>2010-11-05T06:17:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 65: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/04/class-i-medical-device-recall-hospira-symbiq-one-and-two-channel-infuser/</loc>
		<lastmod>2010-11-04T16:49:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 64: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/03/class-i-medical-device-recall-medtronic-octopus-nuvo-tissue-stabilizer-model-tsmics1/</loc>
		<lastmod>2010-11-03T05:07:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 63: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/26/class-i-medical-device-recall-excelsior-medical-disposable-syringe-with-normal-saline-0-9-sodium-chloride-5ml-fill-in-6ml-syringe/</loc>
		<lastmod>2010-10-26T17:19:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 62: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/25/safety-investigation-of-non-coring-huber-needles-updated-october-26-2010/</loc>
		<lastmod>2010-10-25T14:44:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 61: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/21/fda-drug-safety-communication-invirase-saquinavir-labels-now-contain-updated-risk-information-on-abnormal-heart-rhythms/</loc>
		<lastmod>2010-10-21T15:46:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 60: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/15/class-i-medical-device-recall-carefusion-corporation-alaris-pc-units-model-8015/</loc>
		<lastmod>2010-10-15T17:18:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 59: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/15/warning-letters-2010/</loc>
		<lastmod>2010-10-15T04:30:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 58: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/15/fda-drug-safety-communication-safety-update-for-osteoporosis-drugs-bisphosphonates-and-atypical-fractures/</loc>
		<lastmod>2010-10-15T04:30:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 57: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/15/questions-and-answers-on-unapproved-chelation-products/</loc>
		<lastmod>2010-10-15T04:30:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 56: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/13/class-i-medical-device-recall-multi-med-inc-huber-non-coring-needles-and-finished-devices-containing-huber-needles-labeled-as-all-med-medical-products-inc-and-marquette-medica-2/</loc>
		<lastmod>2010-10-14T00:48:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 55: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/13/class-i-medical-device-recall-westmed-inc-bageasy-manual-resuscitation-devices/</loc>
		<lastmod>2010-10-14T00:48:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 54: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/13/bisphosphonates-osteoporosis-drugs-label-change/</loc>
		<lastmod>2010-10-14T00:48:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 53: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/13/complete-list-of-substantially-equivalent-510k-device-applications/</loc>
		<lastmod>2010-10-13T10:48:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 51: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/12/class-i-medical-device-recall-multi-med-inc-huber-non-coring-needles-and-finished-devices-containing-huber-needles-labeled-as-all-med-medical-products-inc-and-marquette-medica/</loc>
		<lastmod>2010-10-12T22:17:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 52: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/12/public-workshop/</loc>
		<lastmod>2010-10-12T22:17:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 50: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/08/fda-drug-safety-communication-fda-recommends-against-the-continued-use-of-meridia-sibutramine/</loc>
		<lastmod>2010-10-09T03:25:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 49: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/08/7345-848/</loc>
		<lastmod>2010-10-09T03:25:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 48: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/06/new-and-generic-drug-approvals/</loc>
		<lastmod>2010-10-07T00:42:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 47: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/06/guidance-for-industry-and-fda-staff/</loc>
		<lastmod>2010-10-07T00:42:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 46: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/06/safe-use-initiative-opportunities-for-collaboration/</loc>
		<lastmod>2010-10-06T11:59:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 45: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/05/fda-patient-safety-news-for-october-2010/</loc>
		<lastmod>2010-10-05T22:46:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 44: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/04/fda-patient-safety-news-for-august-2010/</loc>
		<lastmod>2010-10-04T17:48:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 43: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/04/documents-the-center-for-devices-and-radiological-health-is-considering-for-development-fy11/</loc>
		<lastmod>2010-10-04T17:48:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 42: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/29/cpsc-and-fda-warn-against-using-infant-sleep-positioners-because-of-suffocation-risk-initial-communication/</loc>
		<lastmod>2010-09-29T19:48:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 41: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/29/draft-guidance-for-industry-and-fda-staff-2/</loc>
		<lastmod>2010-09-29T07:06:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 39: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/information-regarding-insulin-storage-and-switching-between-products-in-an-emergency/</loc>
		<lastmod>2010-09-28T00:06:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 40: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/information-regarding-insulin-storage-and-switching-between-products-in-an-emergency-2/</loc>
		<lastmod>2010-09-28T00:06:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 38: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/guidance-for-industry-and-fda-staff-impact/</loc>
		<lastmod>2010-09-27T17:09:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 37: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/medical-devices-technology-innovation-partnership-md-tip-workshop-october-26-2010/</loc>
		<lastmod>2010-09-27T17:09:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 36: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/aami-and-fda-summit-on-infusion-devices-oct-5-6-2010-registration-deadline-september-24/</loc>
		<lastmod>2010-09-27T17:09:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 34: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/fda-drug-safety-communication-new-warnings-for-using-gadolinium-based-contrast-agents-in-patients-with-kidney-dysfunction/</loc>
		<lastmod>2010-09-27T10:12:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 35: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/safe-drug-use-after-a-natural-disaster/</loc>
		<lastmod>2010-09-27T10:12:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 33: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/fda-drug-safety-communication-new-dosing-recommendations-to-prevent-potential-valcyte-valganciclovir-overdose-in-pediatric-transplant-patients/</loc>
		<lastmod>2010-09-27T10:12:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 32: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/class-i-medical-device-recall-symbiq-one-and-two-channel-infusers/</loc>
		<lastmod>2010-09-27T04:03:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 31: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/safety-investigation-of-patient-burns-associated-with-electric-dental-handpieces-and-electric-oral-bone-cutting-handpieces/</loc>
		<lastmod>2010-09-27T04:03:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 30: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/27/draft-guidance-for-industry-and-fda-staff/</loc>
		<lastmod>2010-09-27T04:03:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 29: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/26/august-30-2010-clarification-letter/</loc>
		<lastmod>2010-09-27T00:36:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 28: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/26/gadolinium-based-contrast-agents-class-labeling-change/</loc>
		<lastmod>2010-09-27T00:30:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 27: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/26/hospira-symbiq-one-channel-and-two-channel-infusers-class-i-recall/</loc>
		<lastmod>2010-09-27T00:30:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 26: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/26/national-drug-code-directory/</loc>
		<lastmod>2010-09-27T00:27:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 25: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/26/electronic-orange-book-eob-query-data-files/</loc>
		<lastmod>2010-09-27T00:27:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 24: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/26/fda-drug-safety-communication-ongoing-safety-review-of-actos-pioglitazone-and-potential-increased-risk-of-bladder-cancer-after-two-years-exposure/</loc>
		<lastmod>2010-09-27T00:26:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 22: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/10/09/aptivus%c2%ae-tipranavir-capsules/</loc>
		<lastmod>2007-10-09T18:19:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 17: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/08/08/sancturar-xr-by-indevus-pharmaceuticals-treatment-of-overactive-bladder/</loc>
		<lastmod>2007-08-08T22:41:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 18: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/08/08/selzentrytm-maraviroc-tablets-by-pfizer-new-class-of-oral-hiv-medicines/</loc>
		<lastmod>2007-08-08T22:41:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 16: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/08/08/generic-protonix%c2%ae-pantoprazole-sodium-by-teva-pharmaceutical/</loc>
		<lastmod>2007-08-08T22:31:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 15: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/08/01/generic-zaditor%e2%84%a2-ketotifen-fumarate-by-akorn/</loc>
		<lastmod>2007-08-01T15:16:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 14: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/08/01/14/</loc>
		<lastmod>2007-08-01T15:12:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 12: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/18/prestige%c2%ae-cervical-disc-system/</loc>
		<lastmod>2007-07-18T15:54:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 11: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/18/generic-toradol-akorn-strides-ketorolac-tromethamine/</loc>
		<lastmod>2007-07-18T15:45:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 10: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/12/fda-approves-customvue-monovision-lasik/</loc>
		<lastmod>2007-07-12T20:49:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 9: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/12/generic-tenormin-atenolol-by-caraco/</loc>
		<lastmod>2007-07-12T17:54:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 8: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/12/generic-norvasc-amlodipine-besylate-by-roxane-laboratories/</loc>
		<lastmod>2007-07-12T17:43:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 7: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/12/generic-lioresal-baclofen-by-lannett/</loc>
		<lastmod>2007-07-12T17:42:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 6: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/12/fda-approves-exelon-patch-from-novartis/</loc>
		<lastmod>2007-07-12T05:21:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 5: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/12/generic-dostinex-and-cabaser-cabergoline-by-barr/</loc>
		<lastmod>2007-07-12T05:05:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: Priority report of postID 4: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/12/generic-lamisil-terbinafine-hydrochloride-by-teva/</loc>
		<lastmod>2007-07-12T04:54:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.1</priority>
	</url>
<!-- Debug: End Postings -->
<!-- Debug: Start Cats -->
	<url>
		<loc>http://www.effectivemedicine.org/category/generic-drugs/</loc>
		<changefreq>weekly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/category/medical-device/</loc>
		<changefreq>weekly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/category/new-drugs/</loc>
		<changefreq>weekly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/category/procedures/</loc>
		<changefreq>weekly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/category/uncategorized/</loc>
		<changefreq>weekly</changefreq>
		<priority>0.5</priority>
	</url>
<!-- Debug: End Cats -->
<!-- Debug: Start Archive -->
	<url>
		<loc>http://www.effectivemedicine.org/2012/02/</loc>
		<lastmod>2012-02-22T21:36:12+00:00</lastmod>
		<changefreq>daily</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2012/01/</loc>
		<lastmod>2012-01-31T20:00:33+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/12/</loc>
		<lastmod>2011-12-31T08:45:13+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/11/</loc>
		<lastmod>2011-11-30T18:05:50+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/10/</loc>
		<lastmod>2011-10-31T17:45:57+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/09/</loc>
		<lastmod>2011-09-30T22:46:35+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/08/</loc>
		<lastmod>2011-08-31T06:27:39+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/07/</loc>
		<lastmod>2011-07-30T08:42:34+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/06/</loc>
		<lastmod>2011-06-30T21:41:45+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/05/</loc>
		<lastmod>2011-05-31T22:43:52+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/04/</loc>
		<lastmod>2011-04-30T13:05:26+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/03/</loc>
		<lastmod>2011-03-31T19:35:47+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2011/01/</loc>
		<lastmod>2011-01-21T01:41:49+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2010/12/</loc>
		<lastmod>2010-12-30T02:08:36+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2010/11/</loc>
		<lastmod>2010-11-30T21:21:23+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2010/10/</loc>
		<lastmod>2010-10-26T17:19:29+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2010/09/</loc>
		<lastmod>2010-09-29T19:48:29+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2007/10/</loc>
		<lastmod>2007-10-09T18:19:52+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2007/08/</loc>
		<lastmod>2007-08-08T22:38:57+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
	<url>
		<loc>http://www.effectivemedicine.org/2007/07/</loc>
		<lastmod>2007-07-18T15:54:45+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.5</priority>
	</url>
<!-- Debug: End Archive -->
<!-- Debug: Start Custom Pages -->
<!-- Debug: End Custom Pages -->
<!-- Debug: Start additional URLs -->
<!-- Debug: End additional URLs -->
</urlset>
